<!DOCTYPE drug_guide PUBLIC "-//ES//DTD drug_guide DTD version 3.1//EN//XML" "Y:\WWW1\tools\Drugs\3_1_drug.dtd">
<drug_guide isbn="9780323448260">
	<alpha letter="g">
		<monograph id="1" status="active">
			<mono_name>gabapentin (Rx)</mono_name>
			<info>
				<pronunciation>(gab′a-pen-tin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x212">Gralise</tradename>
					<tradename id="tnidelem4x211">Horizant</tradename>
					<tradename id="tnidelem4x210">Neurontin</tradename>
				</tradenames>
				<class type="func"> Anticonvulsant</class>
				<class type="chem"> GABA analogue</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x31">
				<para>
					<confusion>
						<tradename id="tnidelem4x310">Neurontin</tradename>
						<drug type="generic" refid="idelem4x310">Noroxin/Neoral</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x35">
				<sec_title>Action:</sec_title>
				<para>Mechanism unknown; may increase seizure threshold; structurally similar to GABA; gabapentin binding sites in neocortex, hippocampus</para>
			</section>
			<section type="uses" id="sidelem4x40">
				<sec_title>Uses:</sec_title>
				<para>Adjunct treatment of partial seizures, with/without generalization in patients &gt;12 yr; adjunct for partial seizures in children 3-12 yr, postherpetic neuralgia, primary restless leg syndrome in adults</para>
				<section type="none" id="sidelem4x45">
					<section type="none" id="sidelem4x46">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Tremors with multiple sclerosis (MS), neuropathic pain, bipolar disorder, migraine prophylaxis, diabetic neuropathy, nystagmus, pruritus, spasticity, menopause, hot flashes, ALS, MS</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x51">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product</para>
				<section type="none" id="sidelem4x56">
					<section type="none" id="sidelem4x57">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;3 yr, geriatric patients, renal disease, hemodialysis, suicidal thoughts, depression</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x62">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x65">
					<section type="none" id="sidelem4x66">
						<sec_title>Adjunctive use in partial seizures with or without secondary generalized tonic-clonic seizures (Neurontin only)</sec_title>
						<section type="none" id="sidelem4x74">
							<label>•</label>
							<sec_title>Adult and child &gt;12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x74">
									<item>
										<label>•</label>
										<para> 900-1800 mg/day in 3 divided doses; may titrate to 1800-2400 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x81">
							<label>•</label>
							<sec_title>Child 3-12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x81">
									<item>
										<label>•</label>
										<para> 10-15 mg/kg/day in 3 divided doses, initially titrate dose upward over approximately 3 days; if &gt;5 yr old, use 25-35 mg/kg/day; if 3-4 yr old, 40 mg/kg/day divided in 3 doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x85">
						<sec_title>Postherpetic neuralgia</sec_title>
						<section type="none" id="sidelem4x93">
							<label>•</label>
							<sec_title>Adult<route> PO (Neurontin)</route></sec_title>
							<para>
								<list id="lidelem4x93">
									<item>
										<label>•</label>
										<para> 300 mg on day 1, 600 mg/day divided bid on day 2, 900 mg/day divided tid, may titrate to 1800-3600 mg divided tid if needed;  300 mg on day 1, 600 mg on day 2, 900 mg on days 3-6, 1200 mg on days 7-10, 1500 mg on days 11-14, 1800 mg on day 15 and thereafter; : 600 mg in <emphasis style="smallcaps">am</emphasis> × 3 days, day 4 give 600 mg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x106">
						<sec_title>Moderate to severe restless leg syndrome (RLS) (Horizant only)</sec_title>
						<section type="none" id="sidelem4x114">
							<label>•</label>
							<sec_title>Adult<route> PO EXT REL</route></sec_title>
							<para>
								<list id="lidelem4x114">
									<item>
										<label>•</label>
										<para> 600 mg daily with food at about 5 <emphasis style="smallcaps">pm</emphasis>; if dose missed, take next day at 5 <emphasis style="smallcaps">pm</emphasis></para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x123">
						<sec_title>
							<emphasis style="bold">Renal dose</emphasis>
						</sec_title>
						<section type="none" id="sidelem4x132">
							<label>•</label>
							<sec_title>Adult and child &gt;12 yr<route> PO immediate release</route></sec_title>
						</section>
						<section type="none" id="sidelem4x138">
							<label>•</label>
							<sec_title>Adult<route> PO extended-release tablets (Gralise tablets only)</route></sec_title>
							<para>
								<list id="lidelem4x138">
									<item>
										<label>•</label>
										<para>
											<emphasis style="smallcaps">
												<emphasis style="bold">am</emphasis>
											</emphasis>
											<emphasis style="smallcaps">
												<emphasis style="bold">am</emphasis>
											</emphasis>
											<emphasis style="smallcaps">
												<emphasis style="bold">am</emphasis>
											</emphasis>
											<emphasis style="smallcaps">
												<emphasis style="bold">am</emphasis>
											</emphasis>&lt;<emphasis style="smallcaps">
												<emphasis style="bold">am</emphasis>
											</emphasis></para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x170">
						<sec_title>Uremic pruritus in hemodialysis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x178">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x178">
									<item>
										<label>•</label>
										<para> 300 mg 3×/wk or 400 mg 2×/wk, at end of hemodialysis ×4 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x182">
						<sec_title>Brachioradical pruritus (unlabeled)</sec_title>
						<section type="none" id="sidelem4x190">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x190">
									<item>
										<label>•</label>
										<para> 300-1800 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x194">
						<sec_title>ALS (unlabeled)</sec_title>
						<section type="none" id="sidelem4x202">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x202">
									<item>
										<label>•</label>
										<para> 1000 mg/day in divided doses × 6 mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x206">
						<sec_title>Pendular/congenital nystagmus (unlabeled)</sec_title>
						<section type="none" id="sidelem4x214">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x214">
									<item>
										<label>•</label>
										<para> 900 mg/day in divided doses initially, up to 2400 mg/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x218">
						<sec_title>Spasticity in MS (unlabeled)</sec_title>
						<section type="none" id="sidelem4x226">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x226">
									<item>
										<label>•</label>
										<para> 600-1200 mg/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x230">
						<sec_title>Available forms:</sec_title>
						<para> Caps 100, 300, 400 mg; tabs 600, 800 mg; Horizant: ext rel tab 300, 600 mg; oral sol 250 mg/5 ml; ext rel tab (Gralise): 300, 600 mg</para>
					</section>
					<section type="none" id="sidelem4x235">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x240">
								<item>
									<label>•</label>
									<para>Do not crush or chew caps, ext rel tabs; caps may be opened and contents put in applesauce or dissolved in juice; scored tabs may be cut in half</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x245">
								<item>
									<label>•</label>
									<para>2 hr apart when giving antacids</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x250">
								<item>
									<label>•</label>
									<para>Give without regard to meals immediate release</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x258">
							<label>•</label>
							<sec_title>
								<route>Gradually withdraw over 7 days; abrupt withdrawal may precipitate seizures</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x261">
								<item>
									<label>•</label>
									<para>Beginning dose at bedtime to minimize daytime drowsiness</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x269">
							<label>•</label>
							<sec_title>Oral sol</sec_title>
							<para>
								<list id="lidelem4x269">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Oral sol:</emphasis> measure with calibrated device, refrigerate</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x276">
							<label>•</label>
							<sec_title>Ext rel</sec_title>
							<para>
								<list id="lidelem4x276">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Ext rel:</emphasis> give with food at about 5 <emphasis style="smallcaps">pm</emphasis>; bioavailability increased with food; swallow whole; </para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x285">
								<item>
									<label>•</label>
									<para>Store at room temperature away from heat and light</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x290">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x293">
					<section type="none" id="sidelem4x294">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Drowsiness, confusion,</emphasis> dizziness, fatigue, anxiety, somnolence, ataxia, amnesia, abnormal thinking, unsteady gait, <emphasis style="italic">depression;</emphasis> children 3-12 yr old, emotional lability, aggression, thought disorder, hyperkinesia, hostility, <emphasis style="bold">seizures, suicidal ideation,</emphasis> impaired cognition, euphoria</para>
					</section>
					<section type="none" id="sidelem4x308">
						<sec_title>CV:</sec_title>
						<para> Vasodilation, peripheral edema, hypotension, hypertension</para>
					</section>
					<section type="none" id="sidelem4x313">
						<sec_title>EENT:</sec_title>
						<para> Dry mouth, blurred vision, <emphasis style="italic">diplopia,</emphasis> nystagmus, conjunctivitis; otitis media (child 3-12 yr)</para>
					</section>
					<section type="none" id="sidelem4x321">
						<sec_title>GI:</sec_title>
						<para> Constipation/diarrhea, weight gain, increased appetite, dental abnormalities, nausea, vomiting; diarrhea (Gralise)</para>
					</section>
					<section type="none" id="sidelem4x326">
						<sec_title>GU:</sec_title>
						<para> Impotence, bleeding, <emphasis style="italic">UTI</emphasis></para>
					</section>
					<section type="none" id="sidelem4x333">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x340">
						<sec_title>INTEG:</sec_title>
						<para> Pruritus, abrasion, <emphasis style="bold">Stevens-Johnson syndrome,</emphasis> acne vulgaris</para>
					</section>
					<section type="none" id="sidelem4x348">
						<sec_title>MS:</sec_title>
						<para> Myalgia, back pain, gout</para>
					</section>
					<section type="none" id="sidelem4x353">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Rhinitis,</emphasis> pharyngitis, cough, upper respiratory infection (child 3-12 yr)</para>
					</section>
					<section type="none" id="sidelem4x361">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Drug reaction with eosinophilia and systemic symptoms (DRESS);</emphasis> dehydration (child 3-12 yr)</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x369">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Protein binding &lt;3% not metabolized; excreted in urine (unchanged); elimination half-life 5-7 hr; immediate release peak 2 hr, ext rel peak 8 hr (Gralise); 5-7 hr (Horizant)</para>
			</section>
			<section type="interactions" id="sidelem4x374">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—alcohol, sedatives, antihistamines, all other CNS depressants</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> gabapentin levels—antacids, sevelamar, cimetidine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of—HYDROcodone</para>
				<section type="none" id="sidelem4x389">
					<section type="none" id="sidelem4x390">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">False positive:</emphasis> urinary protein using Ames N-multistix SG</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x397">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x400">
					<section type="none" id="sidelem4x401">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x409">
							<label>•</label>
							<sec_title>Seizures</sec_title>
							<para>
								<list id="lidelem4x409">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Seizures:</emphasis> aura, location, duration, frequency, activity at onset</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x417">
							<label>•</label>
							<sec_title>Pain</sec_title>
							<para>
								<list id="lidelem4x417">
									<item>
										<label>
											<emphasis style="italic">•</emphasis>
										</label>
										<para>
											<emphasis style="bold">Pain:</emphasis> location, duration, characteristics if using for chronic pain, migraine</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x423">
								<item>
									<para>
										<emphasis alert="nurse">Mental status: mood, sensorium, affect, behavioral changes, suicidal thoughts/behaviors; if mental status changes, notify prescriber</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x428">
								<item>
									<label>•</label>
									<para>Eye problems, need for ophthalmic exam before, during, after treatment (slit lamp, funduscopy, tonometry)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x433">
								<item>
									<label>•</label>
									<para>WBC, gabapentin level (therapeutic 5.9-21 mcg/ml, toxic &gt;85 mcg/ml), serum creatinine/BUN, weight</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x441">
							<label>•</label>
							<sec_title>
								<route>Drug reaction with eosinophilia and systemic symptoms</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x447">
							<label>•</label>
							<sec_title>Seizure precautions</sec_title>
							<para>
								<list id="lidelem4x447">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Seizure precautions:</emphasis> padded side rails; move objects that may harm patient (Gralise)</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x451">
								<item>
									<label>•</label>
									<para>Increased fluids, bulk in diet for constipation</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x456">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x460">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased seizure activity; decrease in chronic pain</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x466">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x471">
								<item>
									<label>•</label>
									<para>To carry emergency ID stating patient’s name, products taken, condition, prescriber’s name and phone number</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x476">
								<item>
									<label>•</label>
									<para>To avoid driving, other activities that require alertness because dizziness, drowsiness may occur</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x484">
							<label>•</label>
							<sec_title>
								<route>Not to discontinue medication quickly after long-term use; to taper over ≥1 wk because withdrawal-precipitated seizures may occur; not to double doses if dose is missed; to take if 2 hr or more before next dose</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x487">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy planned or suspected; to avoid breastfeeding</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x492">
								<item>
									<label>•</label>
									<para>Not to use within 2 hr of antacid, may take regular release without regard to meals; ext rel should be taken with food; to take as directed, doses interval should not be ≥12 hr</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x497">
								<item>
									<label>•</label>
									<para>To take ext rel product with food</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x502">
								<item>
									<label>•</label>
									<para>To keep oral solution refrigerated</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="2" status="active">
			<mono_name>galantamine (Rx)</mono_name>
			<info>
				<pronunciation>(gah-lan′tah-meen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x5122">Razadyne</tradename>
					<tradename id="tnidelem4x5121">Razadyne ER</tradename>
					<tradename id="tnidelem4x5120">
						<country code="CAN">Reminyl </country>
					</tradename>
				</tradenames>
				<class type="func"> Anti-Alzheimer agent</class>
				<class type="chem"> Centrally acting cholinesterase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x524">
				<sec_title>Action:</sec_title>
				<para>Enhances cholinergic functioning by increasing acetylcholine in cerebral cortex</para>
			</section>
			<section type="uses" id="sidelem4x529">
				<sec_title>Uses:</sec_title>
				<para>Mild to moderate dementia of Alzheimer’s disease, dementia with Lewy bodies</para>
				<section type="none" id="sidelem4x534">
					<section type="none" id="sidelem4x535">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Vascular dementia, Pick’s disease</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x540">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, GI bleeding, jaundice, renal failure, children</para>
				<section type="none" id="sidelem4x545">
					<section type="none" id="sidelem4x546">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), geriatric patients, respiratory/renal/hepatic/cardiac disease, seizure disorder, peptic ulcer, asthma, bradycardia, heart block, surgery, urinary tract obstruction, breastfeeding</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x551">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x559">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x559">
							<item>
								<label>•</label>
								<para> 4 mg bid with morning and evening meals; after 4 wk or more, may increase to 8 mg bid; may increase to 12 mg bid after another 4 wk, usual dose 16-24 mg/day in 2 divided doses;  8 mg/day in <emphasis style="smallcaps">am</emphasis>; may increase to 16 mg/day after 4 wk and 24 mg/day after another 4 wk</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x569">
					<section type="none" id="sidelem4x570">
						<sec_title>
							<emphasis style="bold">Hepatic dose</emphasis>
						</sec_title>
						<section type="none" id="sidelem4x579">
							<label>•</label>
							<sec_title>Adult<route> PO Child-Pugh 7-9, max 16 mg/day; Child-Pugh 10-15, avoid use</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x582">
						<sec_title>
							<emphasis style="bold">Renal dose</emphasis>
						</sec_title>
						<section type="none" id="sidelem4x591">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 10-70 ml/min, max 16 mg/day; CCr &lt;9 ml/min, avoid use</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x594">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 4, 8, 12 mg; ext rel caps 8, 16, 24 mg; oral sol 4 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x599">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x602">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x607">
									<item>
										<label>•</label>
										<para>With meals; take with morning and evening meal (immediate rel); morning (ext rel)</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x613">
									<item>
										<label>•</label>
										<para>Dose increase after minimum of 4 wk at prior dose; if dose is interrupted for ≥3 days, restart at lower dose, titrate to current dose</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x618">
									<item>
										<label>•</label>
										<para>Ext rel in <emphasis style="smallcaps">am</emphasis> with food; do not crush, open, or chew</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x629">
								<label>•</label>
								<sec_title>Oral sol</sec_title>
								<para>
									<list id="lidelem4x629">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Oral sol:</emphasis> use pipette provided, put in liquid and have patient consume</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x633">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x636">
					<section type="none" id="sidelem4x637">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Tremors, insomnia,</emphasis> depression, dizziness, headache, somnolence, fatigue</para>
					</section>
					<section type="none" id="sidelem4x645">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Bradycardia,</emphasis> chest pain, <emphasis style="bold">AV block</emphasis></para>
					</section>
					<section type="none" id="sidelem4x655">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, abdominal distress, flatulence,</emphasis> diarrhea</para>
					</section>
					<section type="none" id="sidelem4x663">
						<sec_title>GU:</sec_title>
						<para> Urinary incontinence, bladder outflow obstruction, hematuria</para>
					</section>
					<section type="none" id="sidelem4x668">
						<sec_title>HEMA:</sec_title>
						<para> Anemia</para>
					</section>
					<section type="none" id="sidelem4x673">
						<sec_title>META:</sec_title>
						<para> Weight decrease</para>
					</section>
					<section type="none" id="sidelem4x678">
						<sec_title>MS:</sec_title>
						<para> Asthenia</para>
					</section>
					<section type="none" id="sidelem4x683">
						<sec_title>RESP:</sec_title>
						<para> Upper respiratory tract infection, rhinitis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x688">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly and completely absorbed; metabolized by CYP2D6, 3A4; excreted via kidneys; clearance is lower in geriatric patients, hepatic disease; clearance is 20% lower in females; elimination half-life 7 hr; 18% protein binding, peak 1 hr</para>
			</section>
			<section type="interactions" id="sidelem4x693">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> synergistic effect—cholinomimetics, other cholinesterase inhibitors</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> galantamine effect—CYP3A4, CYP2D6 inhibitors (antiretroviral protease inhibitors, ketoconazole, erythromycin, conivaptan, delaviridine, diltiazem, efavirenz, fluconazole, fluvoxaMINE, imatinib, itraconazole, clarithromycin, troleandomycin, nefazodone, niCARdipine, verapamil, voriconazole, zafirlukast)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> GI effects—NSAIDs</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> galantamine effect—CYP3A4, CYP2D6 inducers (bosentan, carBAMazepine, nevirapine, OXcarbazepine, phenytoin, fosphenytoin/rifabutin, rifampin, rifapentine, troglitazone), anticholinergics</para>
				<section type="none" id="sidelem4x712">
					<section type="none" id="sidelem4x713">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> galantamine effect—St. John’s wort</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x720">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x723">
					<section type="none" id="sidelem4x724">
						<sec_title>Assess:</sec_title>
						<para>
							<emphasis style="bold">Alzheimer’s disease:</emphasis> mental status: affect, mood, behavioral changes, depression, attention, confusion; neurologic status: long- and short-term memory, cognitive functioning<list id="lidelem4x731">
								<item>
									<label>•</label>
									<para>Hepatic/renal studies: AST, ALT, alk phos, LDH, bilirubin, CBC; BUN, creatinine</para>
								</item>
								<item>
									<label>•</label>
									<para>For severe GI effects: nausea, vomiting, anorexia, weight loss; GU effects: urinary retardation, bladder obstruction</para>
								</item>
								<item>
									<label>•</label>
									<para>B/P, heart rate, respiration during initial treatment: bradycardia/AV block may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>Fluid status: ensure adequate hydration</para>
								</item>
								<item>
									<label>•</label>
									<para>Assistance with ambulation during beginning therapy</para>
								</item>
							</list></para>
					</section>
					<section type="none" id="sidelem4x757">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x761">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased confusion</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x767">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x771">
								<item>
									<label>•</label>
									<para>To notify all prescribers of use</para>
								</item>
								<item>
									<label>•</label>
									<para>About correct procedure for giving oral sol using instruction sheet provided</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber of severe GI effects; hypo/hypertension, slow heart rate</para>
								</item>
								<item>
									<label>•</label>
									<para>That product is not a cure but relieves symptoms</para>
								</item>
								<item>
									<label>•</label>
									<para>That results may take several wk or mo to occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To take with food to minimize side effects</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="3" status="active">
			<mono_name>ganciclovir (Rx)</mono_name>
			<info>
				<pronunciation>(gan-sye′kloe-vir)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x8072">Cytovene</tradename>
					<tradename id="tnidelem4x8071">Vitrasert</tradename>
					<tradename id="tnidelem4x8070">Zirgan</tradename>
				</tradenames>
				<class type="func"> Antiviral</class>
				<class type="chem"> Synthetic nucleoside analog</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x817">
				<para>
					<confusion>
						<tradename id="tnidelem4x8170">Cytovene</tradename>
						<drug type="generic" refid="idelem4x8170">Cytosar</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x821">
				<sec_title>Action:</sec_title>
				<para>Inhibits replication of herpesviruses; competitively inhibits human CMV DNA polymerase and is incorporated, resulting in termination of DNA elongation</para>
			</section>
			<section type="uses" id="sidelem4x827">
				<sec_title>Uses:</sec_title>
				<para>Cytomegalovirus (CMV) retinitis in immunocompromised persons, including those with AIDS, after indirect ophthalmoscopy confirms diagnosis; prophylaxis for CMV in transplantation; ophthalmic: acute herpes keratitis</para>
				<section type="none" id="sidelem4x832">
					<section type="none" id="sidelem4x833">
						<sec_title>Unlabeled uses:</sec_title>
						<para> CMV pneumonia in organ transplant patients; CMV gastroenteritis, esophagitis, colitis; CMV pneumonitis, congenital CMV disease; Epstein-Barr virus; herpes simplex types 1, 2; varicella-zoster, hepatitis B</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x838">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to acyclovir, ganciclovir</para>
				<para>
					<bbw>Absolute neutrophil count &lt;500, platelet count &lt;25,000 (intravitreal)</bbw>
				</para>
				<section type="none" id="sidelem4x853">
					<section type="none" id="sidelem4x854">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;6 mo, geriatric patients, preexisting cytopenias, renal function impairment, radiation therapy, hypersensitivity to famciclovir, penciclovir, valacyclovir, valganciclovir</para>
						<para>
							<bbw>Secondary malignancy, bone marrow suppression, anemia, infertility, neutropenia</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x869">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x872">
					<section type="none" id="sidelem4x873">
						<sec_title>Prevention of CMV</sec_title>
						<section type="none" id="sidelem4x881">
							<label>•</label>
							<sec_title>Adult/adolescent<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x881">
									<item>
										<label>•</label>
										<para> 5 mg/kg/dose over 1 hr q12hr × 1-2 wk, then 5 mg/kg/day 7 day/wk, or 6 mg/kg/day × 5 days/wk;  1000 mg tid starting 10 days posttransplant × 14 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x888">
						<sec_title>Induction treatment</sec_title>
						<section type="none" id="sidelem4x896">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x896">
									<item>
										<label>•</label>
										<para> 5 mg/kg/dose given over 1 hr, q12hr × 2-3 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x900">
						<sec_title>Maintenance treatment</sec_title>
						<section type="none" id="sidelem4x908">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x908">
									<item>
										<label>•</label>
										<para> 5 mg/kg/dose given over 1 hr, daily × 7 days/wk or 6 mg/kg/day × 5 days/wk;  1000 mg tid with food or 500 mg q3hr while awake for 6 doses;  4.5 mg implant</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x918">
						<sec_title>Acute herpes keratitis</sec_title>
						<section type="none" id="sidelem4x926">
							<label>•</label>
							<sec_title>Adult/adolescent/child ≥2 yr<route> OPHTH</route></sec_title>
							<para>
								<list id="lidelem4x926">
									<item>
										<label>•</label>
										<para> 1 drop in affected eye 5 times daily</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x930">
						<sec_title>
							<emphasis style="bold">Renal dose</emphasis>
						</sec_title>
						<section type="none" id="sidelem4x939">
							<label>•</label>
							<sec_title>Adult<route> IV CCr 50-69 ml/min, reduce to 2.5 mg/kg q12hr (induction), 2.5 mg/kg q24hr (maintenance); PO 1500 mg/day or 500 mg tid; IV CCr 25-49 ml/min, reduce to 2.5 mg/kg (induction); 1.25 mg/kg q24hr (maintenance); PO 1000 mg/day or 500 mg bid; IV CCr 10-24 ml/min, reduce to 1.25 mg/kg q24hr (induction); 0.625 mg/kg q24hr (maintenance); PO 500 mg/day; IV CCr &lt;10 ml/min, reduce to 1.25 mg/kg 3×/wk after hemodialysis (induction); 0.625 mg/kg 3×/wk after hemodialysis (maintenance); PO 500 mg 3×/wk after hemodialysis</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x942">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj 500 mg/vial; caps 250, 500 mg; implant, intraviteral 4.5 mg; ophth gel 0.15% (Zirgan)</para>
					</section>
					<section type="none" id="sidelem4x947">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x950">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x954">
									<item>
										<label>•</label>
										<para>With food and a full glass of water</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not open, crush capsules</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x965">
							<sec_title>Intravitreal implant route</sec_title>
							<para>
								<list id="lidelem4x969">
									<item>
										<label>•</label>
										<para>Implanted by surgeon only</para>
									</item>
									<item>
										<label>•</label>
										<para>Handle carefully to prevent damage to coating</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x980">
							<sec_title>Intravitreal inj route (unlabeled)</sec_title>
							<para>
								<list id="lidelem4x984">
									<item>
										<label>•</label>
										<para>Reconstitute and dilute IV powder to 2 mg/0.1 ml or 5 mg/0.1 ml, depending on dose; injected using TB syringe</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x990">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x994">
									<item>
										<label>•</label>
										<para>Mixed in biologic cabinet using gown, gloves, mask; use cytotoxic handling procedures</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1000">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x1004">
									<item>
										<label>•</label>
										<para>IV after reconstituting 500 mg/10 ml sterile water for inj (50 mg/ml); shake; further dilute in 50-250 ml D<emphasis style="inf">5</emphasis>W, 0.9% NaCl, LR, Ringer’s and run over 1 hr; use infusion pump, in-line filter, flush line well before and after product</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not give by bolus IV, IM, SUBCUT inj</para>
									</item>
									<item>
										<label>•</label>
										<para>Use reconstituted sol within 24 hr; do not refrigerate or freeze</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Allopurinol, amphotericin B cholesteryl, CISplatin, cyclophosphamide, DOXOrubicin liposome, enalaprilat, etoposide, filgrastim, fluconazole, gatifloxacin, granisetron, linezolid, melphalan, methotrexate, PACLitaxel, propofol, remifentanil, tacrolimus, teniposide, thiotepa</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1029">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1032">
					<section type="none" id="sidelem4x1033">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Fever,</emphasis> chills, <emphasis style="bold">coma,</emphasis><emphasis style="italic">confusion</emphasis>, abnormal thoughts, dizziness, bizarre dreams, <emphasis style="italic">headache</emphasis>, psychosis, tremors, somnolence, <emphasis style="italic">paresthesia</emphasis>, <emphasis style="italic">weakness,</emphasis><emphasis style="bold">seizures,</emphasis> peripheral neuropathy</para>
					</section>
					<section type="none" id="sidelem4x1057">
						<sec_title>CV:</sec_title>
						<para> Dysrhythmia, hypo/hypertension</para>
					</section>
					<section type="none" id="sidelem4x1062">
						<sec_title>EENT:</sec_title>
						<para> Retinal detachment in CMV retinitis, ocular hypertension, ocular pain, conjunctival scarring, cataracts</para>
					</section>
					<section type="none" id="sidelem4x1067">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Abnormal LFTs, nausea, vomiting, anorexia, diarrhea, abdominal pain,</emphasis><emphasis style="bold">hemorrhage, perforation, pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1076">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Hematuria,</emphasis><emphasis style="italic">increased creatinine,</emphasis> BUN, infertility, decreased sperm count</para>
					</section>
					<section type="none" id="sidelem4x1086">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Granulocytopenia, thrombocytopenia, irreversible neutropenia, anemia, eosinophilia, pancytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1093">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash</emphasis>, alopecia, <emphasis style="italic">pruritus</emphasis>, urticaria, pain at site, phlebitis</para>
					</section>
					<section type="none" id="sidelem4x1104">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1109">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 3-4<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr; excreted by kidneys (unchanged); crosses blood-brain barrier, CSF, increased bioavailability with fatty foods</para>
			</section>
			<section type="interactions" id="sidelem4x1120">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: severe granulocytopenia—zidovudine, antineoplastics, radiation; do not give together</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> ganciclovir toxicity—adriamycin, amphotericin B, cycloSPORINE, dapsone, DOXOrubicin, flucytosine, pentamidine, probenecid, trimethoprim-sulfamethoxazole combinations, vinBLAStine, vinCRIStine, other nucleoside analogs, mycophenolate, tenofovir, tacrolimus, aminoglycosides, NSAIDs</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> seizures—imipenem/cilastatin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> didanosine effect—didanosine</para>
				<section type="none" id="sidelem4x1138">
					<section type="none" id="sidelem4x1139">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs, creatinine</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb, WBC, platelets, neutrophils, granulocytes</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1150">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1153">
					<section type="none" id="sidelem4x1154">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Secondary malignancy: avoid direct contact with powder in caps/solution, if skin contact occurs, wash thoroughly with soap and water; do not get in the eyes</bbw>
						</para>
						<section type="none" id="sidelem4x1172">
							<label>•</label>
							<sec_title>CMV retinitis</sec_title>
							<para>
								<list id="lidelem4x1172">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">CMV retinitis:</emphasis> culture should be completed before starting treatment (urine, blood, throat), ophthalmic exam</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1179">
							<label>•</label>
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x1179">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infection:</emphasis> increased temperature, sore throat, chills, fever; report to prescriber</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Leukopenia/neutropenia/thrombocytopenia:</emphasis> CBC, WBCs, platelets q2days during 2×/day dosing and then q1wk for leukopenia with daily WBC count in patients with prior leukopenia with other nucleoside analogs or for whom leukopenia counts are &lt;1000 cells/mm3 at start of treatment</bbw>
						</para>
						<para>
							<list id="lidelem4x1199">
								<item>
									<label>•</label>
									<para>Serum creatinine or CCr ≥q2wk, BUN; LFTs; ophthalmic exam</para>
								</item>
								<item>
									<label>•</label>
									<para>For seizures, dysrhythmias</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1210">
						<sec_title>Evaluate:</sec_title>
						<para/>
						<para>
							<list id="lidelem4x1215">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased symptoms or prevention of CMV</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1221">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1226">
								<item>
									<label>•</label>
									<para>Do not wear contact lenses while using gel</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1231">
								<item>
									<label>•</label>
									<para>That product does not cure condition; that regular blood tests, ophthalmologic exams are necessary</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1236">
								<item>
									<label>•</label>
									<para>That major toxicities may necessitate discontinuing product
<bbw>To use contraception during treatment and that infertility may occur; to use barrier contraception for 90 days after treatment; may cause reversible infertility at lower doses, irreversible infertility at higher doses</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1250">
								<item>
									<label>•</label>
									<para>To take PO with food</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1257">
								<item>
									<para>
										<emphasis alert="nurse">To report infection: fever, chills, sore throat; blood dyscrasias: bruising, bleeding, petechiae; to avoid crowds, persons with respiratory infections</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1263">
								<item>
									<para>
										<emphasis alert="nurse">To report itching, redness or eye pain</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="4" status="active">
			<mono_name>ganciclovir ophthalmic</mono_name>
			<section type="none" id="sidelem4x1271">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="5" status="active">
			<mono_name>gatifloxacin</mono_name>
			<info>
				<pronunciation>(ga-ti-floks′a-sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x12801">Zymar</tradename>
					<tradename id="tnidelem4x12800">Zymaxid</tradename>
				</tradenames>
				<class type="func"> Ophthalmic antiinfective</class>
				<class type="chem"> Fluoroquinolone</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x1290">
				<para>
					<confusion>
						<tradename id="tnidelem4x12900">gatifloxacin</tradename>
						<drug type="generic" refid="idelem4x12900">levofloxacin/moxifloxacin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x1294">
				<sec_title>Action:</sec_title>
				<para>Inhibits DNA gyrase, thereby decreasing bacterial replication</para>
			</section>
			<section type="uses" id="sidelem4x1299">
				<sec_title>Uses:</sec_title>
				<para>Bacterial conjunctivitis</para>
			</section>
			<section type="contra" id="sidelem4x1304">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or fluoroquinolones, infants &lt;1 yr</para>
				<section type="none" id="sidelem4x1309">
					<section type="none" id="sidelem4x1310">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1315">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1318">
					<section type="none" id="sidelem4x1319">
						<sec_title>Bacterial conjunctivitis</sec_title>
						<section type="none" id="sidelem4x1327">
							<label>•</label>
							<sec_title>Adult/adolescent/child ≥1 yr<route> OPHTH SOL</route></sec_title>
							<para>
								<list id="lidelem4x1327">
									<item>
										<label>•</label>
										<para> instill 1 drop (0.5% sol) q2hr while awake</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1331">
						<sec_title>Available forms:</sec_title>
						<para> Ophthalmic solution 0.5%</para>
					</section>
					<section type="none" id="sidelem4x1336">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x1339">
							<sec_title>Ophthalmic route</sec_title>
							<para>
								<list id="lidelem4x1343">
									<item>
										<label>•</label>
										<para>Commercially available ophthalmic solutions are not for injection subconjunctivally or into the anterior chamber of the eye</para>
									</item>
									<item>
										<label>•</label>
										<para>Apply topically to the eye, taking care to avoid contamination, up to 8×/day × 2 days, then 1 drop up to 4×/day × 5 more days; zymaxid: 1 drop into affected eyes q2hr while awake up to 8×/day, then 1 drop 2-4×/day while awake on days 2-7; do not touch the tip of the dropper to the eye, fingertips, or other surface</para>
									</item>
									<item>
										<label>•</label>
										<para>Apply pressure to lacrimal sac for 1 min after instillation</para>
									</item>
									<item>
										<label>•</label>
										<para>Avoid wearing contact lenses during treatment</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1364">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1367">
					<section type="none" id="sidelem4x1368">
						<sec_title>EENT:</sec_title>
						<para> Hypersensitivity, irritation, redness, tearing, keratitis, blepharitis, taste changes, ocular discharge/hemorrhage/irritation/pain</para>
					</section>
					<section type="none" id="sidelem4x1373">
						<sec_title>CNS:</sec_title>
						<para> Headache</para>
					</section>
					<section type="none" id="sidelem4x1378">
						<sec_title>GI:</sec_title>
						<para> Taste change</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1383">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Unknown</para>
			</section>
			<section type="considerations" id="sidelem4x1388">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1391">
					<section type="none" id="sidelem4x1392">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x1400">
							<label>•</label>
							<sec_title>
								<route>Allergic reaction</route>
							</sec_title>
							<para>
								<list id="lidelem4x1400">
									<item>
										<label>•</label>
										<para>: hypersensitivity, discontinue product</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1404">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1408">
								<item>
									<label>•</label>
									<para>Decreased ophthalmic infection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1414">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x1417">
							<sec_title>Ophthalmic route</sec_title>
							<para>
								<list id="lidelem4x1421">
									<item>
										<label>•</label>
										<para>To apply topically to the eye, taking care to avoid contamination; for ophthalmic use only</para>
									</item>
									<item>
										<label>•</label>
										<para>Not to touch the tip of the dropper to the eye, fingertips, or other surface</para>
									</item>
									<item>
										<label>•</label>
										<para>To apply pressure to lacrimal sac for 1 min after instillation</para>
									</item>
									<item>
										<label>•</label>
										<para>To avoid wearing contact lenses during treatment</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="6" status="active" ha="yes">
			<mono_name> gemcitabine (Rx)</mono_name>
			<info>
				<pronunciation>(jem-sit′a-been)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x14490">Gemzar</tradename>
				</tradenames>
				<class type="func"> Antineoplastic—miscellaneous</class>
				<class type="chem"> Pyrimidine analog</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x1459">
				<para>
					<confusion>
						<tradename id="tnidelem4x14590">Gemzar</tradename>
						<drug type="generic" refid="idelem4x14590">Zinecard</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x1463">
				<sec_title>Action:</sec_title>
				<para>Exhibits antitumor activity by killing cells undergoing DNA synthesis (S phase) and blocking G1/S-phase boundary</para>
			</section>
			<section type="uses" id="sidelem4x1468">
				<sec_title>Uses:</sec_title>
				<para>Adenocarcinoma of the pancreas (nonresectable stage II, III, or metastatic stage IV); in combination with CISplatin for inoperable, advanced, or metastatic non–small-cell lung cancer; advanced breast cancer in combination with PACLitaxel; with CARBOplatin for ovarian cancer</para>
				<section type="none" id="sidelem4x1475">
					<section type="none" id="sidelem4x1476">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Bladder cancer, mesothelioma, adjuvant treatment of pancreatic cancer, ovarian cancer single agent, biliary tract cancer, advanced <emphasis style="sans-serif">T</emphasis>-cell lymphoma</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x1484">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, hypersensitivity</para>
				<section type="none" id="sidelem4x1489">
					<section type="none" id="sidelem4x1490">
						<sec_title>Precautions:</sec_title>
						<para> Children, geriatric patients, myelosuppression, radiation therapy, renal/hepatic disease, accidental exposure, alcoholism, dental disease, infection</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1495">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1498">
					<section type="none" id="sidelem4x1499">
						<sec_title>Pancreatic carcinoma (nonresectable stage II, III, IV)</sec_title>
						<section type="none" id="sidelem4x1507">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x1507">
									<item>
										<label>•</label>
										<para> 1000 mg/m<emphasis style="sup">2</emphasis> given over 30 min/wk up to 7 wk, then 1-wk rest period; subsequent cycles should be infused 1×/wk × 3 wk out of every 4 wk depending on hematologic toxicity</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1514">
						<sec_title>Non–small-cell lung cancer</sec_title>
						<section type="none" id="sidelem4x1522">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x1522">
									<item>
										<label>•</label>
										<para> (4-wk schedule) 1000 mg/m<emphasis style="sup">2</emphasis> given over 30 min on days 1, 8, 15, of each 28-day cycle; give CISplatin  100 mg/m<emphasis style="sup">2</emphasis> on day 1 after gemcitabine; 3-wk schedule: 1250 mg/m<emphasis style="sup">2</emphasis> given over 30 min on days 1, 8 of each 21-day cycle; give CISplatin  100 mg/m<emphasis style="sup">2</emphasis> after the infusion of gemcitabine on day 1</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1544">
						<sec_title>Advanced breast cancer</sec_title>
						<section type="none" id="sidelem4x1552">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x1552">
									<item>
										<label>•</label>
										<para> 1250 mg/m<emphasis style="sup">2</emphasis> over 30 min on days 1 and 8 of 21-day cycle; give with PACLitaxel 175 mg/m<emphasis style="sup">2</emphasis> over 3 hr before gemcitabine on day 1</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1562">
						<sec_title>Recurrent ovarian cancer (single agent) (unlabeled)</sec_title>
						<section type="none" id="sidelem4x1570">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x1570">
									<item>
										<label>•</label>
										<para> 1 g/m<emphasis style="sup">2</emphasis>, days 1, 8, 15 of 28-day cycle</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1577">
						<sec_title>Available forms:</sec_title>
						<para> Lyophilized powder for inj 20 mg/ml (10-, 50-ml vials); solution for inj 1 g/26.3 ml, 2 g/52.26 ml, 200 mg/2.56 ml</para>
					</section>
					<section type="none" id="sidelem4x1582">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x1585">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x1590">
									<item>
										<label>•</label>
										<para>Prepare in biologic cabinet using gown, mask, gloves; use cytotoxic handling procedures</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x1595">
									<item>
										<label>•</label>
										<para>After reconstituting with 0.9% NaCl 5 ml/200-mg vial of product or 25 ml/1-g vial of product (38 mg/ml) shake; may be further diluted with 0.9% NaCl to concentrations as low as 0.1 mg/ml; discard unused portions, give over 30 min, do not admix</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x1600">
									<item>
										<label>•</label>
										<para>Diluted solution stable at room temperature for 24 hr, do not refrigerate</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x1605">
									<item>
										<label>•</label>
										<para>Infusion longer than 60 min increase toxicity</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x1613">
								<label>•</label>
								<sec_title>Bone marrow depression<route> CBC, differential, platelet count before each dose; single agent</route></sec_title>
							</section>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alemtuzumab, alfentanil, allopurinol, amifostine, amikacin, aminophylline, ampicillin, anidulafungin, argatroban, aztreonam, bivalirudin, bleomycin, bumetanide, butorphanol, calcium gluconate, caspofungin, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, chlorproMAZINE, cimetidine, ciprofloxacin, CISplatin, clindamycin, cyclophosphamide, cytarabine, DACTINomycin, DAUNOrubicin, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, DOXOrubicin, droperidol, enalaprilat, etoposide, famotidine, floxuridine, fluconazole, fludarabine, fluorouracil, gentamicin, granisetron, haloperidol, heparin, hydrocortisone, HYDROmorphone, IDArubicin, ifosfamide, leucovorin, linezolid, LORazepam, mannitol, meperidine, mesna, metoclopramide, metroNIDAZOLE, minocycline, mitoXANtrone, morphine, nalbuphine, ondansetron, PACLitaxel, promethazine, ranitidine, streptozocin, teniposide, thiotepa, ticarcillin, tigecycline, tobramycin, topotecan, trimethoprim/sulfamethoxazole, vancomycin, vinBLAStine, vinCRIStine, vinorelbine, voriconazole, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1622">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1625">
					<section type="none" id="sidelem4x1626">
						<sec_title>ENDO:</sec_title>
						<para> Hyperglycemia</para>
					</section>
					<section type="none" id="sidelem4x1631">
						<sec_title>GI:</sec_title>
						<para> Diarrhea, <emphasis style="italic">nausea, vomiting,</emphasis> anorexia, constipation, stomatitis, diarrhea, <emphasis style="bold">hepatotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1641">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Proteinuria,</emphasis> hematuria</para>
					</section>
					<section type="none" id="sidelem4x1649">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, anemia, neutropenia, thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1656">
						<sec_title>INTEG:</sec_title>
						<para> Irritation at site, <emphasis style="italic">rash, alopecia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1663">
						<sec_title>META:</sec_title>
						<para> Hypocalcemia, hypokalemia, hypomagnesemia</para>
					</section>
					<section type="none" id="sidelem4x1668">
						<sec_title>RESP: </sec_title>
						<para>
							<emphasis alert="lifethreat">Dyspnea, bronchospasm, pneumonitis</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x1674">
						<sec_title>OTHER:</sec_title>
						<para> <emphasis style="italic">Fever,</emphasis><emphasis style="bold">hemorrhage,</emphasis> infection, flulike symptoms, paresthesia, <emphasis style="italic">peripheral edema,</emphasis> myalgia, <emphasis style="bold">capillary leak syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1689">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 42-379 min, crosses placenta, excretion: renal, 92%-98%</para>
			</section>
			<section type="interactions" id="sidelem4x1694">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding—NSAIDs, alcohol, salicylates, anticoagulants</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> myelosuppression, diarrhea—other antineoplastics, radiation</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antibody response—live virus vaccines</para>
				<section type="none" id="sidelem4x1709">
					<section type="none" id="sidelem4x1710">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> BUN, AST, ALT, alk phos, bilirubin, creatinine</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb, WBC, neutrophils, platelets</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1721">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1724">
					<section type="none" id="sidelem4x1725">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x1733">
							<label>•</label>
							<sec_title>Blood dyscrasias</sec_title>
							<para>
								<list id="lidelem4x1733">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Blood dyscrasias:</emphasis> bruising, bleeding, petechiae</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1737">
								<item>
									<label>•</label>
									<para>I&amp;O, nutritional intake; food preferences: list likes, dislikes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1742">
								<item>
									<label>•</label>
									<para>Renal, hepatic studies before and during treatment; may increase AST, ALT, alk phos, bilirubin, BUN, creatinine, calcium, potassium, glucose, magnesium, urine protein</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1747">
								<item>
									<label>•</label>
									<para>Buccal cavity for dryness, sores, ulceration, white patches, oral pain, bleeding, dysphagia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1752">
								<item>
									<label>•</label>
									<para>GI symptoms: frequency of stools, cramping</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1757">
								<item>
									<label>•</label>
									<para>Signs of dehydration: rapid respirations, poor skin turgor, decreased urine output, dry skin, restlessness, weakness</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1762">
								<item>
									<label>•</label>
									<para>Increased fluid intake to 2-3 L/day to prevent dehydration unless contraindicated</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1767">
								<item>
									<label>•</label>
									<para>Rinsing of mouth tid-qid with water, club soda; brushing of teeth bid-tid with soft brush or cotton-tipped applicator for stomatitis; use unwaxed dental floss</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1772">
								<item>
									<label>•</label>
									<para>Antiemetic agents</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1780">
							<label>•</label>
							<sec_title>Capillary leak syndrome<route> hemo-concentration, decreased albumin, B/P; discontinue if these occur</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x1783">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1787">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in tumor size; decrease in spread of cancer; symptom relief</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1793">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1798">
								<item>
									<label>•</label>
									<para>To avoid foods with citric acid or hot or rough texture if stomatitis is present; to drink adequate fluids; to avoid use with NSAIDs, alcohol, salicylates</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1803">
								<item>
									<label>•</label>
									<para>To report stomatitis and any bleeding, white spots, ulcerations in mouth; to examine mouth daily, report symptoms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1808">
								<item>
									<label>•</label>
									<para>To report signs of anemia: fatigue, headache, faintness, SOB, irritability; hematuria, dysuria</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1816">
							<label>•</label>
							<sec_title>
								<route>To use contraception during therapy and for 4 mo after; pregnancy (D), do not breastfeed</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x1819">
								<item>
									<label>•</label>
									<para>Not to receive vaccinations during treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1824">
								<item>
									<label>•</label>
									<para>About possible hair loss and what can be done</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1829">
								<item>
									<label>•</label>
									<para>To report flulike symptoms, swelling of feet/legs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1834">
								<item>
									<label>•</label>
									<para>To report bruising, bleeding: gums, blood in urine, stool, emesis</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1839">
								<item>
									<label>•</label>
									<para>To avoid crowds, persons with known upper-respiratory infections</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1845">
								<item>
									<label>•</label>
									<para>To avoid use of hard-bristle toothbrush, electric razor</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1853">
							<label>•</label>
							<sec_title>Infection<route> to report sore throat, fever, flulike symptoms immediately</route></sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="7" status="active">
			<mono_name>gemfibrozil (Rx)</mono_name>
			<info>
				<pronunciation>(jem-fi′broe-zil)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x18610">Lopid</tradename>
				</tradenames>
				<class type="func"> Antilipemic</class>
				<class type="chem"> Fibric acid derivative</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x1871">
				<para>
					<confusion>
						<tradename id="tnidelem4x18710">Lopid</tradename>
						<drug type="generic" refid="idelem4x18710">Levbid/Slo-bid</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x1875">
				<sec_title>Action:</sec_title>
				<para>Inhibits biosynthesis of VLDL, decreases triglycerides, production in the liver increases HDL</para>
			</section>
			<section type="uses" id="sidelem4x1880">
				<sec_title>Uses:</sec_title>
				<para>Type IIb, IV, V hyperlipidemia as adjunct with diet therapy, hypertriglyceridemia</para>
			</section>
			<section type="contra" id="sidelem4x1885">
				<sec_title>Contraindications:</sec_title>
				<para>Severe renal/hepatic disease, preexisting gallbladder disease, primary biliary cirrhosis, hypersensitivity</para>
				<section type="none" id="sidelem4x1890">
					<section type="none" id="sidelem4x1891">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, renal disease, cholelithiasis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1896">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1904">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x1904">
							<item>
								<label>•</label>
								<para> 600 mg bid 30 min before <emphasis style="smallcaps">am</emphasis>, <emphasis style="smallcaps">pm</emphasis> meal</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1914">
					<section type="none" id="sidelem4x1915">
						<sec_title>Hepatic/renal dose</sec_title>
						<section type="none" id="sidelem4x1923">
							<label>•</label>
							<sec_title>
								<route>Avoid use</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x1926">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 600 mg; caps 300 mg <country code="CAN">FIX_STRUCTURE Tabs 600 mg; caps 300 mg </country></para>
					</section>
					<section type="none" id="sidelem4x1933">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x1936">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x1940">
									<item>
										<label>•</label>
										<para>30 min before <emphasis style="smallcaps">am</emphasis>, <emphasis style="smallcaps">pm</emphasis> meals</para>
									</item>
									<item>
										<label>•</label>
										<para>Discontinue product if response does not occur within 3 mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1957">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1960">
					<section type="none" id="sidelem4x1961">
						<sec_title>CNS:</sec_title>
						<para> Fatigue, vertigo, headache, paresthesia, dizziness, somnolence</para>
					</section>
					<section type="none" id="sidelem4x1966">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Dyspepsia, diarrhea, abdominal pain,</emphasis> nausea, vomiting</para>
					</section>
					<section type="none" id="sidelem4x1974">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, anemia, eosinophilia, thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1981">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, pruritus</para>
					</section>
					<section type="none" id="sidelem4x1986">
						<sec_title>MISC:</sec_title>
						<para> Taste perversion</para>
					</section>
					<section type="none" id="sidelem4x1991">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="bold">Myopathy, rhabdomyolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1998">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Angioedema, exfoliative dermatitis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2005">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 1-2 hr; plasma protein binding &gt;95%; half-life 1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr; 70% excreted in urine mostly unchanged; metabolized in liver (minimal)</para>
			</section>
			<section type="interactions" id="sidelem4x2016">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x2024">
					<label>•</label>
					<sec_title>
						<route>Do not use with repaglinide, simvastatin</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypoglycemic effect—sulfonylureas, repaglinide</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> anticoagulant properties—warfarin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> risk of myositis, myalgia, rhabdomyolysis—HMG-CoA reductase inhibitors</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of gemfibrozil—bile acid sequestrants, separate by &gt;2 hr</para>
				<section type="none" id="sidelem4x2043">
					<section type="none" id="sidelem4x2044">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs, CK, bilirubin, alkaline phosphatase</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb, Hct, WBC, potassium, eosinophils, platelets</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2055">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2058">
					<section type="none" id="sidelem4x2059">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x2067">
							<label>•</label>
							<sec_title>Hyperlipidemia</sec_title>
							<para>
								<list id="lidelem4x2067">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hyperlipidemia:</emphasis> diet history: fats, triglycerides, cholesterol; if lipids increase, product should be discontinued; LDL, VLDL baseline and periodically</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2074">
							<label>•</label>
							<sec_title>Myopathy, rhabdomyolysis<route> For muscle pain, tenderness; obtain baseline CPK; if elevated or if these occur, product should be discontinued; at greater risk if combined with HMG-Co-A reductase inhibitors</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x2077">
								<item>
									<label>•</label>
									<para>Renal, hepatic studies, CBC, blood glucose if patient is receiving long-term therapy; if LFTs increase, therapy should be discontinued; monitor hematologic and hepatic functions</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2082">
								<item>
									<label>•</label>
									<para>Bowel pattern daily; watch for increasing diarrhea (common)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2087">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2091">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased cholesterol, triglyceride levels; HDL, cholesterol ratios improved</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2098">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2102">
								<item>
									<label>•</label>
									<para>That compliance is needed for positive results; not to double or skip dose, take missed dose as soon as remembered unless almost time for next dose</para>
								</item>
								<item>
									<label>•</label>
									<para>That risk factors should be decreased: high-fat diet, smoking, alcohol consumption, absence of exercise</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber of diarrhea, nausea, vomiting, chills, fever, sore throat, muscle cramps, abdominal cramps, severe flatulence, tendon pain</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid driving, hazardous activities if dizziness, blurred vision occur</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="8" status="active">
			<mono_name>gemifloxacin (Rx)</mono_name>
			<info>
				<pronunciation>(gem-ah-flox′a-sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x21280">Factive</tradename>
				</tradenames>
				<class type="func"> Antiinfective</class>
				<class type="chem"> Fluoroquinolone</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x2138">
				<sec_title>Action:</sec_title>
				<para>Inhibits DNA gyrase, which is an enzyme involved in replication, transcription, and repair of bacterial DNA</para>
			</section>
			<section type="uses" id="sidelem4x2143">
				<sec_title>Uses:</sec_title>
				<para>Acute bacterial exacerbation of chronic bronchitis caused by <emphasis style="italic">Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis;</emphasis> community-acquired pneumonia caused by <emphasis style="italic">Streptococcus pneumoniae</emphasis> including multiproduct-resistant strains, <emphasis style="italic">H. influenzae, M. catarrhalis, Mycoplasma pneumoniae, Chlamydia pneumoniae, Klebsiella pneumoniae</emphasis></para>
			</section>
			<section type="contra" id="sidelem4x2156">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to quinolones</para>
				<section type="none" id="sidelem4x2161">
					<section type="none" id="sidelem4x2162">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, hypokalemia, hypomagnesemia, renal disease, seizure disorders, excessive exposure to sunlight, psychosis, increased intracranial pressure, history of QT interval prolongation, dysrhythmias, myasthenia gravis, torsades de pointes</para>
						<para>
							<bbw>Tendon pain/rupture, tendinitis, myasthenia gravis</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2177">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2185">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x2185">
							<item>
								<label>•</label>
								<para> 320 mg/day × 5-7 days depending on type of infection</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2189">
					<section type="none" id="sidelem4x2190">
						<sec_title>
							<emphasis style="bold">Renal dose</emphasis>
						</sec_title>
						<section type="none" id="sidelem4x2199">
							<label>•</label>
							<sec_title>Adult<route> PO CCr ≤40 ml/min, 160 mg q24hr</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2202">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 320 mg</para>
					</section>
					<section type="none" id="sidelem4x2207">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x2211">
								<item>
									<label>•</label>
									<para>2 hr before or 3 hr after aluminum/magnesium antacids, iron, zinc products, multivitamins, buffered products 2 hr before sucralfate</para>
								</item>
								<item>
									<label>•</label>
									<para>Without regard to food</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2222">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2225">
					<section type="none" id="sidelem4x2226">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, headache,</emphasis> somnolence, depression, insomnia, nervousness, confusion, agitation, <emphasis style="bold">seizures, pseudotumor cerebri</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2236">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">QT prolongation,</emphasis> vasodilation</para>
					</section>
					<section type="none" id="sidelem4x2244">
						<sec_title>EENT:</sec_title>
						<para> Visual disturbances, retinal detachment</para>
					</section>
					<section type="none" id="sidelem4x2249">
						<sec_title>GI:</sec_title>
						<para> Diarrhea, <emphasis style="italic">nausea,</emphasis> vomiting, anorexia, flatulence, heartburn, dry mouth; increased AST, ALT; constipation, abdominal pain, <emphasis style="bold">pseudomembranous colitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2259">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus, urticaria, <emphasis style="italic">photosensitivity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2266">
						<sec_title>MS:</sec_title>
						<para> Tendinitis, <emphasis style="bold">tendon rupture</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2273">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2280">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly absorbed; bioavailability 71%; peak <emphasis style="sup">1</emphasis>⁄<emphasis style="inf">2</emphasis>-2 hr; half-life 4-12 hr; excreted in urine as active product, metabolites</para>
			</section>
			<section type="interactions" id="sidelem4x2291">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS stimulation—NSAIDs</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity of gemifloxacin—probenecid</para>
				<para>
					<emphasis alert="nurse">Increase: QT prolongation—class IA, III antidysrhythmics, tricyclics, amoxapine, maprotiline, phenothiazines, haloperidol, pimozide, risperiDONE, sertindole, ziprasidone, β-blockers, chloroquine, cloZAPine, dasatinib, dolasetron, droperidol, dronedarone, flecainide, halogenated/local anesthetics, local anesthetics, lapatinib, methadone, erythromycin, telithromycin, troleandomycin, octreotide, ondansetron, palonosetron, pentamidine, propafenone, ranolazine, SUNItinib, tacrolimus, vardenafil, vorinostat</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption antacids containing aluminum, magnesium, sucralfate, zinc, iron; give 2 hr before or 3 hr after meals</para>
			</section>
			<section type="considerations" id="sidelem4x2312">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2315">
					<section type="none" id="sidelem4x2316">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x2321">
								<item>
									<label>•</label>
									<para>Renal, hepatic studies: BUN, creatinine, AST, ALT; I&amp;O ratio, electrolytes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2326">
								<item>
									<label>•</label>
									<para>CNS symptoms: insomnia, vertigo, headache, agitation, confusion</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2332">
								<item>
									<para>
										<emphasis alert="nurse">Allergic reactions and anaphylaxis: rash, flushing, urticaria, pruritus, chills, fever, joint pain; may occur a few days after therapy begins; EPINEPHrine and resuscitation equipment should be available for anaphylactic reaction</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2340">
							<label>•</label>
							<sec_title>Pseudomembranous colitis<route> bowel pattern daily; if severe diarrhea, fever, abdominal pain occur, product should be discontinued</route></sec_title>
						</section>
						<section type="none" id="sidelem4x2346">
							<label>•</label>
							<sec_title>QT prolongation<route> avoid use of quinolones in patients with known QT prolongation, females and those with ongoing proarrhythmic conditions (TdP) are at a greater risk; monitor ECG and/or holter monitoring if product is used</route></sec_title>
						</section>
						<section type="none" id="sidelem4x2352">
							<label>•</label>
							<sec_title>Overgrowth of infection</sec_title>
							<para>
								<list id="lidelem4x2352">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Overgrowth of infection:</emphasis> perineal itching, fever, malaise, redness, pain, swelling, drainage, rash, diarrhea, change in cough, sputum
<bbw>
												<emphasis alert="lifethreat">Tendon rupture:</emphasis> tendon pain, inflammation; if present, discontinue use; more common when used with corticosteroids; discontinue immediately if tendon pain, inflammation occurs</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2370">
							<label>•</label>
							<sec_title>Toxic psychosis/pseudotumor cerebri<route> headache, blurred vision, neck/shoulder pain, nausea, vomiting, dizziness, tinnitus; discontinue immediately</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2373">
						<sec_title>Evaluate</sec_title>
						<para>
							<list id="lidelem4x2377">
								<item>
									<label>•</label>
									<para>Therapeutic response: negative C&amp;S, absence of signs, symptoms of infection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2383">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2387">
								<item>
									<label>•</label>
									<para>To take with/without food</para>
								</item>
								<item>
									<label>•</label>
									<para>That fluids must be increased to 2 L/day to avoid crystallization in kidneys</para>
								</item>
								<item>
									<label>•</label>
									<para>That if dizziness or light-headedness occurs, to perform activities with assistance</para>
								</item>
								<item>
									<label>•</label>
									<para>To complete full course of product therapy</para>
								</item>
								<item>
									<label>•</label>
									<para>To contact prescriber if adverse reactions occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid iron- or mineral-containing supplements or aluminum/magnesium antacids, buffered products within 2 hr before and 3 hr after dosing, 2 hr before sucralfate</para>
								</item>
								<item>
									<label>•</label>
									<para>That photosensitivity may occur and sunscreen should be used</para>
								</item>
								<item>
									<label>•</label>
									<para>To use frequent rinsing of mouth, sugarless candy or gum for dry mouth</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid other medication unless approved by prescriber</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="9" status="active">
			<mono_name>gentamicin (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x24360">
						<country code="CAN">Cidomycin </country>
					</tradename>
				</tradenames>
				<class type="func"> Antiinfective</class>
				<class type="chem"> Aminoglycoside</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x2450">
				<para>
					<confusion>
						<tradename id="tnidelem4x24500">gentamicin</tradename>
						<drug type="generic" refid="idelem4x24500">kanamycin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x2454">
				<sec_title>Action:</sec_title>
				<para>Interferes with protein synthesis in bacterial cell by binding to 30S ribosomal subunit, thus causing misreading of genetic code; inaccurate peptide sequence forms in protein chain, thereby causing bacterial death</para>
			</section>
			<section type="uses" id="sidelem4x2459">
				<sec_title>Uses:</sec_title>
				<para>Severe systemic infections of CNS, respiratory, GI, urinary tract, bone, skin, soft tissues caused by susceptible strains of <emphasis style="italic">Pseudomonas aeruginosa, Proteus, Klebsiella, Serratia, Escherichia coli, Enterobacter, Citrobacter, Staphylococcus, Shigella, Salmonella, Acinetobacter, Bacillus anthracis</emphasis></para>
				<section type="none" id="sidelem4x2467">
					<section type="none" id="sidelem4x2468">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Bartonellosis, bronchiectasis, cystic fibrosis, endocarditis prophylaxis, febrile neutropenia, gonorrhea, granuloma inguinale, PID, plaque, surgical infection prophylaxis, tubo-ovarian abscess, tularemia</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x2473">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, other aminoglycosides</para>
				<para>
					<bbw>Pregnancy (D)</bbw>
				</para>
				<section type="none" id="sidelem4x2488">
					<section type="none" id="sidelem4x2489">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, neonates, geriatric patients, pseudomembranous colitis</para>
						<para>
							<bbw>Renal disease, hearing deficits, myasthenia gravis, Parkinson’s disease, infant botulism, neuromuscular disease, tinnitus</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2504">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2507">
					<section type="none" id="sidelem4x2508">
						<sec_title>Severe systemic infections</sec_title>
						<section type="none" id="sidelem4x2516">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x2516">
									<item>
										<label>•</label>
										<para> 3-5 mg/kg/day in divided doses q8hr;  (pulse dosing, once-daily dosing) (unlabeled) 5-7 mg/kg;  3-5 mg/kg/day in divided doses q8hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2529">
							<label>•</label>
							<sec_title>Child<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x2529">
									<item>
										<label>•</label>
										<para> 2-2.5 mg/kg q8hr;  (pulse dosing, once-daily dosing) (unlabeled) 5 mg/kg</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2539">
							<label>•</label>
							<sec_title>Neonate and infant<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x2539">
									<item>
										<label>•</label>
										<para> 2.5 mg/kg q8-12hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2546">
							<label>•</label>
							<sec_title>Neonate &lt;1 wk<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x2546">
									<item>
										<label>•</label>
										<para> 2.5 mg/kg q12</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2550">
						<sec_title>Renal dose-Regular dosing</sec_title>
						<section type="none" id="sidelem4x2558">
							<label>•</label>
							<sec_title>Adult<route> IM/IV CCr 70-100 ml/min, reduce dose by multiplying maintenance dose by 0.85, give q8-12hr; CCr 50-69 ml/min, reduce as above, give q12hr; CCr 25-49 ml/min, reduce as above, give q24hr; CCr &lt;25 ml/min, reduce as above, give based on serum concentrations, give doses after dialysis</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2561">
						<sec_title>Renal dose: extended interval (unlabeled)</sec_title>
						<section type="none" id="sidelem4x2569">
							<label>•</label>
							<sec_title>Adult<route> IV CCr 40-59 ml/min 5-7 mg/kg q36hr; CCr 20-39 ml/min 5-7 mg/kg q48hr; CCr &lt;20 ml/min 5-7 mg/kg once, then base on serial levels</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2572">
						<sec_title>Available forms:</sec_title>
						<para> Inj 10, 40 mg/ml; premixed inj 40, 60, 70, 80, 90, 100, 120/100 ml NS</para>
					</section>
					<section type="none" id="sidelem4x2577">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x2580">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x2584">
									<item>
										<label>•</label>
										<para>IM inj in large muscle mass; rotate inj sites</para>
									</item>
									<item>
										<label>•</label>
										<para>Product in evenly spaced doses to maintain blood level</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2595">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x2599">
									<item>
										<label>•</label>
										<para>After diluting in 50-200 ml NS, D<emphasis style="inf">5</emphasis>W; decrease vol of diluent in child; maintain 0.1% sol run over <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1 hr (adults) or up to 2 hr (children); flush IV line with NS, D<emphasis style="inf">5</emphasis>W after administration</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alatrofloxacin, aldesleukin, alemtuzumab, alfentanil, alprostadil, amifostine, amikacin, aminocaproic acid, aminophylline, amiodarone, amsacrine, anidulafungin, argatroban, arsenic trioxide, ascorbic acid injection, asparaginase, atenolol, atracurium, atropine, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/ gluconate, carboplatin, carmustine, caspofungin, cefamandole, ceFAZolin, cefepime, cefotaxime, cefOXitin, cefpirome, ceftaroline, cefTAZidime, ceftizoxime, ceftRIAXone, cefuroxime, chlorothiazide, chlorpheniramine, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, CISplatin, clarithromycin, clindamycin, cloxacillin, codeine, colistimethate, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, DAUNOrubicin citrate liposome, DAUNOrubicin hydrochloride, dexmedetomidine, dexrazoxane, digoxin, diltiazem, dimenhyDRINATE, diphenhydrAMINE, DOBUTamine, DOCEtaxel, dolasetron, DOPamine, doripenem, doxacurium, doxapram, DOXOrubicin hydrochloride, doxorubicin hydrochloride liposomal, doxycycline, edetate calcium disodium, edetate disodium, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, eptifibatide, ergonovine, ertapenem, erythromycin lactobionate, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, fluorouracil, foscarnet, gallamine, gallium, gatifloxacin, gemcitabine, glycopyrrolate, granisetron, HYDROmorphone, hydrOXYzine, ifosfamide, imipenem-cilastatin, irinotecan, isoproterenol, ketamine, ketorolac, labetalol, lactated ringer’s injection, lansoprazole, lepirudin, leucovorin, levofloxacin, lidocaine, lincomycin, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, mephentermine sulfate, meropenem, mesna, metaraminol, methyldopate, methylPREDNISolone sodium succinate, metoclopramide, metoprolol, metroNIDAZOLE, midazolam, milrinone, minocycline, mitoXANtrone, mivacurium, morphine, multiple vitamins injection, mycophenolate mofetil, nafcillin, nalbuphine, nalorphine, naloxone, netilmicin, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oritavancin, oxaliplatin, oxytocin, PACLitaxel (solvent/surfactant), palonosetron, pamidronate, pancuronium, papaverine, penicillin G potassium/sodium, pentazocine, perphenazine, PHENobarbital, phentolamine, phenylephrine, phytonadione, piperacillin, polymyxin B, posaconazole, potassium acetate/chloride, procainamide, prochlorperazine, prochlorperazine, promazine, promethazine, propranolol, protamine, pyridoxine, quiNIDine gluconate, ranitidine, remifentanil, ringer’s injection, riTUXimab, rocuronium, sargramostim, sodium acetate/, bicarbonate/citrate, streptomycin, succinylcholine, SUFentanil, tacrolimus, telavancin, temocillin, teniposide, theophylline, thiamine, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, TNA (3-in-1), tobramycin, tolazoline, topotecan, TPN (2-in-1), trastuzumab, trimetaphan, tubocurarine, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinBLAStine, vinCRIStine, vinorelbine, vitamin B complex with C, voriconazole, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2623">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2626">
					<section type="none" id="sidelem4x2627">
						<sec_title>CNS:</sec_title>
						<para> Confusion, depression, numbness, tremors, <emphasis style="bold">seizures,</emphasis> muscle twitching, <emphasis style="bold">neurotoxicity,</emphasis> dizziness, vertigo, <emphasis style="bold">encephalopathy,</emphasis> fever, headache, lethargy</para>
					</section>
					<section type="none" id="sidelem4x2641">
						<sec_title>CV:</sec_title>
						<para> Hypo/hypertension, palpitations, edema</para>
					</section>
					<section type="none" id="sidelem4x2646">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="bold">Ototoxicity,</emphasis><emphasis style="italic">deafness,</emphasis> visual disturbances, tinnitus</para>
					</section>
					<section type="none" id="sidelem4x2656">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia;</emphasis> increased ALT, AST, bilirubin; hepatomegaly, <emphasis style="bold">hepatic necrosis,</emphasis> splenomegaly</para>
					</section>
					<section type="none" id="sidelem4x2667">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Oliguria, hematuria, renal damage, azotemia, renal failure, nephrotoxicity,</emphasis> proteinuria</para>
					</section>
					<section type="none" id="sidelem4x2675">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis, thrombocytopenia, leukopenia,</emphasis> eosinophilia, anemia</para>
					</section>
					<section type="none" id="sidelem4x2683">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> burning, urticaria, dermatitis, alopecia, photosensitivity, <emphasis style="bold">anaphylaxis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2693">
						<sec_title>MS:</sec_title>
						<para> Twitching, myasthenia gravis-like symptoms</para>
					</section>
					<section type="none" id="sidelem4x2698">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Apnea</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2705">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Not metabolized, excreted unchanged in urine, crosses placental barrier</para>
				<section type="none" id="sidelem4x2710">
					<section type="none" id="sidelem4x2711">
						<sec_title>IM:</sec_title>
						<para> Onset rapid, peak 30-60 min</para>
					</section>
					<section type="none" id="sidelem4x2716">
						<sec_title>IV:</sec_title>
						<para> Onset immediate; peak 30-90 min; plasma half-life 1-2 hr, infants 6-7 hr; duration 6-8 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x2721">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x2729">
					<label>•</label>
					<sec_title>
						<route>Do not use at the same time or physically mix with penicillins</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects—nondepolarizing neuromuscular blockers, digoxin, entecavir</para>
				<section type="none" id="sidelem4x2747">
					<section type="none" id="sidelem4x2748">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LDH, AST, ALT, bilirubin, BUN, creatinine, eosinophils</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb, WBC, platelet, granulocytes</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2760">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2763">
					<section type="none" id="sidelem4x2764">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Neuromuscular disease (myasthenia gravis, Parkinson’s disease, infant botulism):</emphasis> paresthesias, tetany, positive Chvostek’s/Trousseau’s signs, confusion (adults), tetany, muscle weakness (infants); correct electrolyte imbalance</bbw>
						</para>
						<para>
							<list id="lidelem4x2780">
								<item>
									<label>•</label>
									<para>Weight before treatment; calculation of dosage is usually based on ideal body weight but may be calculated on actual body weight</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Renal disease:</emphasis> I&amp;O ratio, urinalysis daily for proteinuria, cells, casts; report sudden change in urine output; urine pH if product is used for UTI; urine should be kept alkaline; urine for CCr testing, BUN, serum creatinine; lower dosage should be given with renal impairment (CCr &lt;80 ml/min); toxicity is increased in patients with decreased renal function if high doses are given</bbw>
						</para>
						<para>
							<list id="lidelem4x2799">
								<item>
									<label>•</label>
									<para>VS during infusion; watch for hypotension, change in pulse</para>
								</item>
								<item>
									<label>•</label>
									<para>IV site for thrombophlebitis, including pain, redness, swelling q30min, change site if needed; discontinue, apply warm compresses to site</para>
								</item>
								<item>
									<label>•</label>
									<para>Serum peak drawn at 30-60 min after IV infusion or 60 min after IM inj and trough level drawn just before next dose; blood level should be 2-4 times bacteriostatic level; peak (5-10 mcg/ml), trough (0.5-2 mcg/ml), depending on type of infection (based on traditional dosing)</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Hearing deficits:</emphasis> eighth cranial nerve dysfunction by audiometric testing; also ringing, roaring in ears, vertigo; assess hearing before, during, after treatment</bbw>
						</para>
						<para>
							<list id="lidelem4x2829">
								<item>
									<label>•</label>
									<para>Dehydration: high specific gravity, decrease in skin turgor, dry mucous membranes, dark urine</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2837">
							<label>•</label>
							<sec_title>Overgrowth of infection</sec_title>
							<para>
								<list id="lidelem4x2837">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Overgrowth of infection:</emphasis> fever, malaise, redness, pain, swelling, perineal itching, diarrhea, stomatitis, change in cough or sputum</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x2841">
								<item>
									<label>•</label>
									<para>C&amp;S before starting treatment to identify infecting organism</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2849">
							<label>•</label>
							<sec_title>Vestibular dysfunction</sec_title>
							<para>
								<list id="lidelem4x2849">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Vestibular dysfunction:</emphasis> nausea, vomiting, dizziness, headache; product should be discontinued if severe</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x2853">
								<item>
									<label>•</label>
									<para>Inj sites for redness, swelling, abscesses; use warm compresses at site</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2858">
								<item>
									<label>•</label>
									<para>Adequate fluids of 2-3 L/day unless contraindicated to prevent irritation of tubules</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2863">
								<item>
									<label>•</label>
									<para>Supervised ambulation, other safety measures with vestibular dysfunction</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2868">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2872">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of fever, draining wounds, negative C&amp;S after treatment</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2878">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2882">
								<item>
									<label>•</label>
									<para>To report headache, dizziness, symptoms of overgrowth of infection, renal impairment
<bbw>To report loss of hearing; ringing, roaring in ears; feeling of fullness in head</bbw>
</para>
								</item>
								<item>
									<label>•</label>
									<para>To drink adequate fluids</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until reaction is known</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="10" status="active">
			<mono_name>gentamicin (ophthalmic)</mono_name>
			<info>
				<pronunciation>(jen-ta-mye′sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x29121">Gentak</tradename>
					<tradename id="tnidelem4x29120">Garamycin</tradename>
				</tradenames>
				<class type="func"> Ophthalmic antiinfective</class>
				<class type="chem"> Aminoglycoside</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x2922">
				<para>
					<confusion>
						<tradename id="tnidelem4x29220">clindamycin</tradename>
						<drug type="generic" refid="idelem4x29220">tobramycin/erythromycin/vancomycin/GenTeal</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x2926">
				<sec_title>Action:</sec_title>
				<para>Inhibits protein synthesis, thereby decreasing bacterial replication</para>
			</section>
			<section type="uses" id="sidelem4x2931">
				<sec_title>Uses:</sec_title>
				<para>External ocular infections</para>
			</section>
			<section type="contra" id="sidelem4x2937">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or aminoglycosides</para>
				<section type="none" id="sidelem4x2942">
					<section type="none" id="sidelem4x2943">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, corneal healing, local redness/irritation</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2948">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2951">
					<section type="none" id="sidelem4x2952">
						<sec_title>Ophthalmic (solution)</sec_title>
						<section type="none" id="sidelem4x2960">
							<label>•</label>
							<sec_title>Adult/adolescent/child ≥1 mo<route> SOL</route></sec_title>
							<para>
								<list id="lidelem4x2960">
									<item>
										<label>•</label>
										<para> 1-2 drops in affected eye(s) every 4 hr while awake × 2 days, then every 4 hr; severe infections ≤2 drops every 1 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2967">
							<label>•</label>
							<sec_title>Ointment</sec_title>
							<para>
								<list id="lidelem4x2967">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Ointment:</emphasis> apply a small amount (1/2″) to lower conjunctival sac bid or tid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2971">
						<sec_title>Available forms:</sec_title>
						<para> Ophthalmic ointment, ophthalmic solution 0.3%</para>
					</section>
					<section type="none" id="sidelem4x2976">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x2979">
							<sec_title>Ophthalmic route</sec_title>
							<para>
								<list id="lidelem4x2983">
									<item>
										<label>•</label>
										<para>Commercially available ophthalmic solutions are not for injection subconjunctivally or into the anterior chamber of the eye</para>
									</item>
									<item>
										<label>•</label>
										<para>Apply topically to the eye, taking care to avoid contamination</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not to touch the tip of the dropper to the eye, fingertips, or other surface</para>
									</item>
									<item>
										<label>•</label>
										<para>Apply pressure to lacrimal sac for 1 min after instillation</para>
									</item>
									<item>
										<label>•</label>
										<para>To apply the ointment, pull down gently on lower eyelid and apply a thin film of the ointment</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3009">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3012">
					<section type="none" id="sidelem4x3013">
						<sec_title>EENT:</sec_title>
						<para> Burning, hypersensitivity, stinging, blurred vision, hyperemia, corneal ulcers</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3018">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Unknown</para>
			</section>
			<section type="considerations" id="sidelem4x3023">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3026">
					<section type="none" id="sidelem4x3027">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x3035">
							<label>•</label>
							<sec_title>
								<route>Allergic reaction</route>
							</sec_title>
							<para>
								<list id="lidelem4x3035">
									<item>
										<label>•</label>
										<para>: hypersensitivity, discontinue product</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3039">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3043">
								<item>
									<label>•</label>
									<para>Decreased ophthalmic infection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3049">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x3052">
							<sec_title>Ophthalmic route</sec_title>
							<para>
								<list id="lidelem4x3056">
									<item>
										<label>•</label>
										<para>To apply topically to the eye, taking care to avoid contamination; for ophthalmic use only</para>
									</item>
									<item>
										<label>•</label>
										<para>Not to touch the tip of the dropper to the eye, fingertips, or other surface</para>
									</item>
									<item>
										<label>•</label>
										<para>To apply pressure to lacrimal sac for 1 min after instillation</para>
									</item>
									<item>
										<label>•</label>
										<para>To apply the ointment by pulling down gently on lower eyelid and applying a thin film of the ointment</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="11" status="active">
			<mono_name>gentamicin (topical)</mono_name>
			<info>
				<pronunciation>(jen-ta-mye′sin)</pronunciation>
				<class type="func"> Topical antiinfective</class>
				<class type="chem"> Aminoglycoside</class>
			</info>
			<section type="confusion" id="sidelem4x3090">
				<para>
					<confusion>
						<tradename id="tnidelem4x30900">gentamicin</tradename>
						<drug type="generic" refid="idelem4x30900">clindamycin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x3094">
				<sec_title>Action:</sec_title>
				<para>Antibacterial activity results from inhibition of protein synthesis; bactericidal</para>
			</section>
			<section type="uses" id="sidelem4x3099">
				<sec_title>Uses:</sec_title>
				<para>Superficial infections</para>
			</section>
			<section type="contra" id="sidelem4x3104">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or other aminoglycosides</para>
				<section type="none" id="sidelem4x3109">
					<section type="none" id="sidelem4x3110">
						<sec_title>Precautions:</sec_title>
						<para> Infections, local sensitivity</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3115">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3123">
					<label>•</label>
					<sec_title>Adult/child &gt;1 yr</sec_title>
					<para>
						<list id="lidelem4x3123">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Adult/child &gt;1 yr:</emphasis> apply to affected areas tid-qid</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x3127">
					<section type="none" id="sidelem4x3128">
						<sec_title>Available forms:</sec_title>
						<para> Topical cream, ointment 0.1%</para>
					</section>
					<section type="none" id="sidelem4x3133">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x3138">
								<item>
									<label>•</label>
									<para>For external use only; do not use skin products near the eyes, nose, or mouth</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3143">
								<item>
									<label>•</label>
									<para>Wash hands before and after use; wash affected area and gently pat dry</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3151">
							<label>•</label>
							<sec_title>Cream/Ointment</sec_title>
							<para>
								<list id="lidelem4x3151">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Cream/Ointment:</emphasis> Apply to the cleansed affected area, massage gently into affected areas</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3155">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3158">
					<section type="none" id="sidelem4x3159">
						<sec_title>INTEG:</sec_title>
						<para> Rash, irritation, erythema, pruritus</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3164">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Unknown</para>
			</section>
			<section type="considerations" id="sidelem4x3169">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3172">
					<section type="none" id="sidelem4x3173">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x3181">
							<label>•</label>
							<sec_title>
								<route>Allergic reaction</route>
							</sec_title>
							<para>
								<list id="lidelem4x3181">
									<item>
										<label>•</label>
										<para>: hypersensitivity, product may need to be discontinued</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3188">
							<label>•</label>
							<sec_title>
								<route>Infection</route>
							</sec_title>
							<para>
								<list id="lidelem4x3188">
									<item>
										<label>•</label>
										<para>: skin infection</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3193">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3197">
								<item>
									<label>•</label>
									<para>Decreased skin infection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3203">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3208">
								<item>
									<label>•</label>
									<para>To use for external use only; do not use skin products near the eyes, nose, or mouth</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3213">
								<item>
									<label>•</label>
									<para>To wash hands before and after use; wash affected area and gently pat dry</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3221">
							<label>•</label>
							<sec_title>Cream/Ointment</sec_title>
							<para>
								<list id="lidelem4x3221">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Cream/Ointment:</emphasis> to apply to the cleansed affected area and massage gently into affected areas</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="12" status="active" ha="yes">
			<mono_name> glatiramer (Rx)</mono_name>
			<info>
				<pronunciation>(glah-tear′a-meer)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x32320">Copaxone</tradename>
				</tradenames>
				<class type="func"> Multiple sclerosis agent</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x3242">
				<sec_title>Action:</sec_title>
				<para>Unknown; may modify the immune responses responsible for multiple sclerosis (MS)</para>
			</section>
			<section type="uses" id="sidelem4x3247">
				<sec_title>Uses:</sec_title>
				<para>Reduction of the frequency of relapses in patients with relapsing or remitting MS after first clinical episode with MRI results consistent with MS</para>
			</section>
			<section type="contra" id="sidelem4x3252">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or mannitol, IV use</para>
				<section type="none" id="sidelem4x3257">
					<section type="none" id="sidelem4x3258">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children &lt;18 yr, immune disorders, renal disease, infection, vaccinations, geriatric patients</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3263">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3271">
					<label>•</label>
					<sec_title>
						<route>20 mg/ml and 40 mg/ml are not interchangeable</route>
					</sec_title>
				</section>
				<section type="none" id="sidelem4x3277">
					<label>•</label>
					<sec_title>Adult<route> SUBCUT</route></sec_title>
					<para>
						<list id="lidelem4x3277">
							<item>
								<label>•</label>
								<para> 20 mg/day (20 mg/ml solution); 40 mg (40 mg/ml solution) 3×/wk, give ≥48 hr apart</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x3281">
					<section type="none" id="sidelem4x3282">
						<sec_title>Available forms:</sec_title>
						<para> Inj, premixed 20 mg/ml in single-use syringe</para>
					</section>
					<section type="none" id="sidelem4x3287">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x3290">
							<sec_title>SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x3294">
									<item>
										<label>•</label>
										<para>Refrigerate, allow to warm for 20 min; visually inspect for particulate or cloudiness, if present discard; prefilled syringe contents is for single use; administer SUBCUT into hip, thigh, arm; discard unused portion</para>
									</item>
									<item>
										<label>•</label>
										<para>Use SUBCUT route only; do not give IM or IV, do not expel air bubble in prefilled syringe</para>
									</item>
									<item>
										<label>•</label>
										<para>Give 40 mg dose on same 3 days of the week, must be 48 hr apart</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3310">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3313">
					<section type="none" id="sidelem4x3314">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Anxiety, hypertonia, tremor, vertigo,</emphasis> speech disorder, <emphasis style="italic">agitation,</emphasis> confusion, flushing</para>
					</section>
					<section type="none" id="sidelem4x3325">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Migraine, palpitations, syncope, tachycardia, vasodilation,</emphasis> chest pain, hypertension</para>
					</section>
					<section type="none" id="sidelem4x3333">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Ear pain, blurred vision</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3340">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, diarrhea, anorexia, gastroenteritis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3347">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Urinary urgency, dysmenorrhea, vaginal moniliasis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3354">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="italic">Ecchymosis, lymphadenopathy</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3361">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Pruritus, rash, sweating, urticaria, erythema,</emphasis> inj-site reaction</para>
					</section>
					<section type="none" id="sidelem4x3369">
						<sec_title>META:</sec_title>
						<para> Edema, weight gain</para>
					</section>
					<section type="none" id="sidelem4x3374">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="italic">Arthralgia, back pain, neck pain,</emphasis> increased muscle tone</para>
					</section>
					<section type="none" id="sidelem4x3382">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Bronchitis, dyspnea, laryngismus, rhinitis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3389">
				<sec_title>Pharmacokinetics</sec_title>
				<para>May be hydrolyzed locally, may reach regional lymph nodes</para>
			</section>
			<section type="interactions" id="sidelem4x3394">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x3402">
					<label>•</label>
					<sec_title>Increase<route> serious infection—denosumab, natalizumab, roflumilast</route></sec_title>
				</section>
				<section type="none" id="sidelem4x3408">
					<label>•</label>
					<sec_title>Increase</sec_title>
					<para>
						<list id="lidelem4x3408">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Increase:</emphasis> toxicity—leflunomide</para>
							</item>
						</list>
					</para>
				</section>
				<para>Avoid use with live virus vaccines</para>
				<section type="none" id="sidelem4x3414">
					<section type="none" id="sidelem4x3415">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x3419">
								<item>
									<label>•</label>
									<para>Decrease: glatiramer effect—echinacea</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3425">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3428">
					<section type="none" id="sidelem4x3429">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x3433">
								<item>
									<label>•</label>
									<para>CNS symptoms: anxiety, confusion, vertigo</para>
								</item>
								<item>
									<label>•</label>
									<para>GI status: diarrhea, vomiting, abdominal pain, gastroenteritis</para>
								</item>
								<item>
									<label>•</label>
									<para>Cardiac status: tachycardia, palpitations, vasodilation, chest pain</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3450">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3454">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased symptoms of MS</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3460">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3465">
								<item>
									<label>•</label>
									<para>With written, detailed instructions about product; provide initial and return demonstrations on inj procedure; give information about use and disposal of product, inj-site reaction (hives, rash, irritation, severe pain, flushing, chest pain)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3470">
								<item>
									<label>•</label>
									<para>To notify prescribers of allergic reactions including itching, trouble breathing; chest pain, dizziness, sweating</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3475">
								<item>
									<label>•</label>
									<para>That irregular menses, dysmenorrhea, metrorrhagia, breast pain may occur; to use contraception during treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3480">
								<item>
									<label>•</label>
									<para>That if pregnancy is suspected or if nursing to notify prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3485">
								<item>
									<label>•</label>
									<para>Not to change dosing or stop taking product without advice of prescriber</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3493">
							<label>•</label>
							<sec_title>immediate postinjection reaction</sec_title>
							<para>
								<list id="lidelem4x3493">
									<item>
										<label>•</label>
										<para>About <emphasis style="bold">immediate postinjection reaction:</emphasis> flushing, chest pain, palpitations, anxiety, dyspnea, laryngeal constriction, urticaria; does not usually require treatment, may occur months after beginning treatment</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3498">
								<item>
									<label>•</label>
									<para>To take as directed; not to stop product or change schedule; teach on self-injection technique</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3506">
							<label>•</label>
							<sec_title>
								<route>That the 20 mg/ml and 40 mg/ml are not interchangeable</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="13" status="active" ha="yes">
			<mono_name> glimepiride (Rx)</mono_name>
			<info>
				<pronunciation>(glye-me′pi-ride)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x35160">Amaryl</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="14" status="active">
			<mono_name>glipiZIDE (Rx)</mono_name>
			<info>
				<pronunciation>(glip-i′zide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x35231">Glucotrol</tradename>
					<tradename id="tnidelem4x35230">Glucotrol XL</tradename>
				</tradenames>
				<class type="func"> Antidiabetic</class>
				<class type="chem"> Sulfonylurea (2nd generation)</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x3533">
				<para>
					<confusion>
						<tradename id="tnidelem4x35330">glipiZIDE</tradename>
						<drug type="generic" refid="idelem4x35330">Glucotrol/glyBURIDE</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x3537">
				<sec_title>Action:</sec_title>
				<para>Causes functioning β cells in pancreas to release insulin, leading to drop in blood glucose levels; may improve insulin binding to insulin receptors or increase the number of insulin receptors with prolonged administration; may also reduce basal hepatic glucose secretion; not effective if patient lacks functioning β cells</para>
			</section>
			<section type="uses" id="sidelem4x3542">
				<sec_title>Uses:</sec_title>
				<para>Type 2 diabetes mellitus</para>
			</section>
			<section type="contra" id="sidelem4x3547">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to sulfonylureas/sulfonamides, type 1 diabetes, diabetic ketoacidosis</para>
				<section type="none" id="sidelem4x3552">
					<section type="none" id="sidelem4x3553">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), geriatric patients, cardiac disease, severe renal/hepatic disease, G6PD deficiency</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3558">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3561">
					<sec_title>
						<emphasis style="italic">Glimepiride</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x3570">
						<label>•</label>
						<sec_title>Adult<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x3570">
								<item>
									<label>•</label>
									<para> 1-2 mg/day with breakfast, then increase by ≤2 mg/day q1-2wk, max 8 mg/day</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3577">
						<label>•</label>
						<sec_title>Geriatric<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x3577">
								<item>
									<label>•</label>
									<para> 1 mg/day; may increase if needed</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3581">
						<sec_title>Renal/Hepatic dose</sec_title>
						<section type="none" id="sidelem4x3589">
							<label>•</label>
							<sec_title>Adult<route> PO 1 mg/day with breakfast; may titrate upward as needed</route></sec_title>
						</section>
					</section>
				</section>
				<section type="none" id="sidelem4x3592">
					<sec_title>
						<emphasis style="italic">GlipiZIDE</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x3601">
						<label>•</label>
						<sec_title>Adult<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x3601">
								<item>
									<label>•</label>
									<para> 5 mg initially before breakfast, then increase by 2.5-5 mg after several days to desired response; max 40 mg/day in divided doses;  (XL) 5 mg/day with breakfast, may increase to 10 mg/day, max 20 mg/day</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3611">
						<label>•</label>
						<sec_title>Geriatric<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x3611">
								<item>
									<label>•</label>
									<para> 2.5 mg/day; may increase if needed</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3615">
						<sec_title>Hepatic disease</sec_title>
						<section type="none" id="sidelem4x3623">
							<label>•</label>
							<sec_title>Adult<route> PO 2.5 mg initially, then increase to desired response; max 40 mg/day in divided doses or 15 mg/dose</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x3626">
						<sec_title>Available forms:</sec_title>
						<para> <emphasis style="italic">Glimepiride:</emphasis> tabs 1, 2, 4 mg; <emphasis style="italic">glipiZIDE:</emphasis> tabs, scored 5, 10 mg; ext rel tab (XL) 2.5, 5, 10 mg</para>
					</section>
					<section type="none" id="sidelem4x3637">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x3642">
								<item>
									<label>•</label>
									<para>Do not break, crush, or chew ext rel tabs; may crush tabs and mix with fluids if unable to swallow whole</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3651">
							<label>•</label>
							<sec_title>GlipiZIDE</sec_title>
							<para>
								<list id="lidelem4x3651">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">GlipiZIDE:</emphasis> product 30 min before meals (regular release); with breakfast (ext rel); <emphasis style="bold">Glimepiride:</emphasis> with breakfast; if patient is NPO, may need to hold dose to prevent hypoglycemia</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3658">
								<item>
									<label>•</label>
									<para>Gradual conversion from other oral hypoglycemics to these products is not needed; insulin ≥20 units/day, convert using 25% reduction in insulin dose every day or every other day</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3663">
								<item>
									<label>•</label>
									<para>Store in tight, light-resistant container at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3668">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3671">
					<section type="none" id="sidelem4x3672">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, weakness, dizziness, drowsiness,</emphasis> tinnitus, fatigue, vertigo</para>
					</section>
					<section type="none" id="sidelem4x3680">
						<sec_title>ENDO:</sec_title>
						<para> <emphasis style="bold">Hypoglycemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3687">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="bold">Hepatotoxicity, cholestatic jaundice,</emphasis> nausea, vomiting, diarrhea, heartburn</para>
					</section>
					<section type="none" id="sidelem4x3695">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, thrombocytopenia, agranulocytosis, aplastic anemia;</emphasis> increased AST, ALT, alk phos; <emphasis style="bold">pancytopenia, hemolytic anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3705">
						<sec_title>INTEG:</sec_title>
						<para> Rash, allergic reactions, pruritus, urticaria, eczema, photosensitivity, erythema, allergic vasculitis</para>
					</section>
					<section type="none" id="sidelem4x3710">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Serious hypersensitivity</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3717">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x3720">
					<section type="none" id="sidelem4x3721">
						<sec_title>PO:</sec_title>
						<para> Completely absorbed by GI route; <emphasis style="bold">glipiZIDE:</emphasis> onset 1-1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr, peak 2-3 hr, duration 12-24 hr, half-life 2-4 hr; <emphasis style="bold">glimepiride:</emphasis> peak 2-3 hr, half-life 5 hr; metabolized in liver, excreted in urine, 90%-95% plasma-protein bound</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x3738">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x3742">
						<item>
							<label>•</label>
							<para>May mask symptoms of hypoglycemia: β-blockers</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of digoxin, glycosides, cyclosporine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypoglycemic effects—insulin, MAOIs, cimetidine, chloramphenicol, guanethidine, methyldopa, NSAIDs, salicylates, probenecid, androgens, anticoagulants, clofibrate, fenfluramine, fluconazole, gemfibrozil, histamine H<emphasis style="inf">2</emphasis> antagonists, magnesium salts, phenylbutazone, sulfinpyrazone, sulfonamides, tricyclics, urinary acidifiers, clarithromycin, fibric acid derivatives, voriconazole</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> hypoglycemic effect—thiazide diuretics, rifampin, isoniazid, cholestyramine, diazoxide, hydantoins, urinary alkalinizers, charcoal, corticosteroids, colesevelam</para>
				<section type="none" id="sidelem4x3763">
					<section type="none" id="sidelem4x3764">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> antidiabetic effect—garlic, horse chestnut</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> hypoglycemic effect—green tea</para>
					</section>
					<section type="none" id="sidelem4x3775">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT, LDH, BUN, creatinine</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3782">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3785">
					<section type="none" id="sidelem4x3786">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x3794">
							<label>•</label>
							<sec_title>
								<route>Hypo/hyperglycemic reaction</route>
							</sec_title>
							<para>
								<list id="lidelem4x3794">
									<item>
										<label>•</label>
										<para> that can occur soon after meals; for severe hypoglycemia give IV D<emphasis style="inf">50</emphasis>W, then IV dextrose solution</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3801">
								<item>
									<label>•</label>
									<para>Blood glucose, A1c levels during treatment to determine diabetes control</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3807">
								<item>
									<para>
										<emphasis alert="nurse">Blood dyscrasias: CBC at baseline and throughout treatment; report decreased blood count</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3812">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3816">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in polyuria, polydipsia, polyphagia; clear sensorium; absence of dizziness; stable gait; improved serum glucose, A1c</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3822">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3826">
								<item>
									<label>•</label>
									<para>Not to drink alcohol; about disulfiram reaction (nausea, headache, cramps, flushing, hypoglycemia)</para>
								</item>
								<item>
									<label>•</label>
									<para>To report bleeding, bruising, weight gain, edema, SOB, weakness, sore throat, swelling in ankles, rash</para>
								</item>
								<item>
									<label>•</label>
									<para>To check for symptoms of cholestatic jaundice: dark urine, pruritus, yellow sclera; prescriber should be notified</para>
								</item>
								<item>
									<label>•</label>
									<para>About symptoms of hypo/hyperglycemia, what to do about each; to have glucagon emergency kit available; to carry sugar packets</para>
								</item>
								<item>
									<label>•</label>
									<para>That product must be continued on daily basis; about consequences of discontinuing product abruptly; to take product in morning to prevent hypoglycemic reactions at night</para>
								</item>
								<item>
									<label>•</label>
									<para>To use sunscreen or stay out of the sun, wear protective clothing (photosensitivity)</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid OTC medications unless ordered by prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>That diabetes is a lifelong illness; product will not cure disease</para>
								</item>
								<item>
									<label>•</label>
									<para>That all food in diet plan must be eaten to prevent hypoglycemia; to continue weight control, dietary restrictions, exercise, hygiene</para>
								</item>
								<item>
									<label>•</label>
									<para>To carry emergency ID with prescriber and medication information</para>
								</item>
								<item>
									<label>•</label>
									<para>To test using blood glucose meter while taking this product</para>
								</item>
								<item>
									<label>•</label>
									<para>That ext rel tab may appear in stool</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="15" status="active">
			<mono_name>glucagon</mono_name>
			<info>
				<pronunciation>(gloo′ka-gon)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x38980">GlucaGen</tradename>
				</tradenames>
				<class type="func"> Antihypoglycemic</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x3904">
				<sec_title>Action:</sec_title>
				<para>Increases in blood glucose, relaxation of smooth muscle of the GI tract, and a positive inotropic and chronotropic effect on the heart; increases in blood glucose are secondary to stimulation of glycogenolysis</para>
			</section>
			<section type="uses" id="sidelem4x3909">
				<sec_title>Uses:</sec_title>
				<para>Hypoglycemia, used to temporarily inhibit movement of GI tract as a diagnostic test</para>
			</section>
			<section type="contra" id="sidelem4x3914">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, pheochromocytoma, insulinoma</para>
				<section type="none" id="sidelem4x3919">
					<section type="none" id="sidelem4x3920">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, cardiac disease, adrenal insufficiency</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3925">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3928">
					<section type="none" id="sidelem4x3929">
						<sec_title>Hypoglycemia in those with diabetes mellitus</sec_title>
						<section type="none" id="sidelem4x3937">
							<label>•</label>
							<sec_title>Adult/adolescent/child ≥55 lb (25 kg)<route> IM/IV/SUBCUT (GlucaGen)</route></sec_title>
							<para>
								<list id="lidelem4x3937">
									<item>
										<label>•</label>
										<para> 1 mg (1 IU)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3944">
							<label>•</label>
							<sec_title>Child &lt;55 lb (25 kg) or &lt;6-8 yr<route> IM/IV/SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x3944">
									<item>
										<label>•</label>
										<para> 0.5 mg (0.5 IU)(Glucagon)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3951">
							<label>•</label>
							<sec_title>Adult/adolescent/child ≥44 lb (20 kg)<route> IM/IV/SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x3951">
									<item>
										<label>•</label>
										<para> (Glucagon) 1 mg (1 IU)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3958">
							<label>•</label>
							<sec_title>Child &lt;44 lb (20 kg)</sec_title>
							<para>
								<list id="lidelem4x3958">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Child &lt;44 lb (20 kg):</emphasis> (Glucagon) 0.5 mg (0.5 IU) or 0.02-0.03 mg/kg (IU/kg) max/mg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3962">
						<sec_title>Severe hypoglycemia</sec_title>
						<para>
							<emphasis style="bold">Neonates: IM/IV/SUBCUT</emphasis> 0.2 mg/kg/dose, max 1 mg/dose; cont infusion (unlabeled): 0.5-1 mg/day</para>
					</section>
					<section type="none" id="sidelem4x3969">
						<sec_title>Available forms:</sec_title>
						<para> Powder for injection 1-mg vial</para>
					</section>
					<section type="none" id="sidelem4x3974">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x3978">
								<item>
									<label>•</label>
									<para>Visually inspect for particulate matter and discoloration before use</para>
								</item>
							</list>
						</para>
						<para>
							<emphasis style="bold">Reconstitution:</emphasis> Reconstitute with 1 ml of sterile water for injection or with diluent supplied by the manufacturer; the reconstituted injection should be clear and of water-like consistency (1 mg/ml); discard any unused portion</para>
						<section type="none" id="sidelem4x3988">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x3992">
									<item>
										<label>•</label>
										<para>Inject into a large muscle mass; aspirate before injection to avoid injection into a blood vessel</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3998">
							<sec_title>SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x4002">
									<item>
										<label>•</label>
										<para>Inject, taking care not to inject intradermally</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4008">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x4012">
									<item>
										<label>•</label>
										<para>Inject directly into a vein at a rate ≤1 IU/min (mg/min); may be given through line running D<emphasis style="inf">5</emphasis>W or given at the same time as a bolus of dextrose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4021">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4024">
					<section type="none" id="sidelem4x4025">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, headache</para>
					</section>
					<section type="none" id="sidelem4x4030">
						<sec_title>CV:</sec_title>
						<para> Hypotension</para>
					</section>
					<section type="none" id="sidelem4x4035">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting</para>
					</section>
					<section type="none" id="sidelem4x4040">
						<sec_title>SYST:</sec_title>
						<para> Hypersensitivity</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4045">
				<sec_title>Pharmacokinetics</sec_title>
				<para>
					<emphasis style="bold">IV:</emphasis> Onset immediate, peak 30 min, duration 1-1<emphasis style="sup">1</emphasis>⁄<emphasis style="inf">2</emphasis> hr</para>
				<para>
					<emphasis style="bold">IM/SUBCUT:</emphasis> Onset 5-10 min, peak 13-20 min, duration 12-30 min</para>
			</section>
			<section type="interactions" id="sidelem4x4062">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—anticoagulants</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of insulin, oral antidiabetics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> B/P and heart rate—β-blockers</para>
			</section>
			<section type="considerations" id="sidelem4x4078">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4081">
					<section type="none" id="sidelem4x4082">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x4090">
							<label>•</label>
							<sec_title>Hypoglycemia</sec_title>
							<para>
								<list id="lidelem4x4090">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypoglycemia:</emphasis> monitor glucose levels before and after product use; use other products to control hypoglycemia if patient is conscious</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4094">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4098">
								<item>
									<label>•</label>
									<para>Decreased hypoglycemia</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4104">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4108">
								<item>
									<label>•</label>
									<para>How to use this product, symptoms of hypoglycemia, instruct patient in use of oral glucose when hypoglycemia occurs, use this product only when patient is unable to swallow</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to use outdated product</para>
								</item>
								<item>
									<label>•</label>
									<para>Have all patients carry a sugar source at all times</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="16" status="active">
			<mono_name>glucarpidase</mono_name>
			<info>
				<pronunciation>(glu-car-pie′dase)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x41290">Voraxaze</tradename>
				</tradenames>
				<class type="func"> Recombinant bacterial enzyme</class>
			</info>
			<section type="actions" id="sidelem4x4135">
				<sec_title>Action:</sec_title>
				<para>A recombinant bacterial enzyme that hydrolyzes glutamate residue from methotrexate and provides an alternate nonrenal pathway for methotrexate elimination in patients with renal dysfunction during high-dose methotrexate treatment; as a result of its enzymatic action, converts methotrexate to its inactive metabolites</para>
			</section>
			<section type="uses" id="sidelem4x4140">
				<sec_title>Uses:</sec_title>
				<para>The treatment of methotrexate toxicity (methotrexate plasma concentrations &gt;1 μmol/l in those with delayed methotrexate clearance due to impaired renal function</para>
				<section type="none" id="sidelem4x4145">
					<section type="none" id="sidelem4x4146">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4151">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4159">
					<label>•</label>
					<sec_title>Adult/adolescent/child<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x4159">
							<item>
								<label>•</label>
								<para> 50 units/kg over 5 min; continue to give leucovorin, IV hydration, urinary alkalinization as needed</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x4163">
					<section type="none" id="sidelem4x4164">
						<sec_title>Available forms:</sec_title>
						<para> Sol for IV 1000 units</para>
					</section>
					<section type="none" id="sidelem4x4169">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x4172">
							<sec_title>IV direct route</sec_title>
							<para>
								<list id="lidelem4x4176">
									<item>
										<label>•</label>
										<para>Visually inspect parenteral products for particulate matter and discoloration before administration</para>
									</item>
									<item>
										<label>•</label>
										<para>Reconstitution: add 1 ml of sterile saline for injection to vial, roll and tilt the vial gently to mix; do not shake; flush the IV line, then inject as a bolus inj over 5 min; flush the IV line again</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not administer to patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered)</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not administer to patients with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate</para>
									</item>
									<item>
										<label>•</label>
										<para>Continue to administer leucovorin after glucarpidase, but do not administer leucovorin within 2 hr before or after glucarpidase; for the first 48 hr after glucarpidase administration, administer the same leucovorin dose as given before glucarpidase; after 48 hr after glucarpidase, administer leucovorin based on the measured methotrexate concentrations; do not discontinue therapy with leucovorin based on the determination of a single methotrexate concentration below the leucovorin treatment threshold; continue leucovorin until the methotrexate concentration has been maintained below the leucovorin treatment threshold for a minimum of 3 days; use of a chromatographic method to determine methotrexate concentration is needed for the first 48 hr after glucarpidase receipt</para>
									</item>
									<item>
										<label>•</label>
										<para>Continue hydration and alkalinization of the urine as needed</para>
									</item>
									<item>
										<label>•</label>
										<para>Store reconstituted solution refrigerated ≤4 hr; discard any unused product, no preservative is present</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4212">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4215">
					<section type="none" id="sidelem4x4216">
						<sec_title>CNS:</sec_title>
						<para> Paresthesias, headache</para>
					</section>
					<section type="none" id="sidelem4x4221">
						<sec_title>CV:</sec_title>
						<para> Hypo/hypertension</para>
					</section>
					<section type="none" id="sidelem4x4226">
						<sec_title>EENT:</sec_title>
						<para> Throat irritation or tightness</para>
					</section>
					<section type="none" id="sidelem4x4232">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting</para>
					</section>
					<section type="none" id="sidelem4x4237">
						<sec_title>INTEG:</sec_title>
						<para> Flushing, hot, burning sensation; rash, hypersensitivity, <emphasis style="bold">serious allergic reactions</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4244">
						<sec_title>SYST:</sec_title>
						<para> Antibody formation</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4249">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Elimination half-life of 5.6 hr, methotrexate concentrations reduced 97% within 15 min</para>
			</section>
			<section type="interactions" id="sidelem4x4254">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Decrease:</emphasis> elucarpidase level—PEMEtrexed, PRALAtrexate; avoid concurrent use</para>
			</section>
			<section type="considerations" id="sidelem4x4261">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4264">
					<section type="none" id="sidelem4x4265">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x4269">
								<item>
									<label>•</label>
									<para>Continue monitoring of methotrexate blood levels, renal status (creatinine/BUN) after glucarpidase is given; methotrexate concentrations within 48 hr of glucarpidase are only reliable measure by a chromatographic method; leucovorin receipt is needed until methotrexate level has been maintained below leucovorin treatment threshold for a minimum of 3 days</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4275">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4279">
								<item>
									<label>•</label>
									<para>For resolution of methotrexate toxicity</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4285">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x4293">
							<label>•</label>
							<sec_title>To immediately report any infusion-related reactions<route> fever, chills, flushing, feeling hot, rash, hives, itching, throat tightness or breathing problems, tingling, numbness, or headache</route></sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="17" status="active" ha="yes">
			<mono_name> glyBURIDE (Rx)</mono_name>
			<info>
				<pronunciation>(glye′byoor-ide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x43032">DiaBeta</tradename>
					<tradename id="tnidelem4x43031"/>
					<tradename id="tnidelem4x43030">Glynase PresTab</tradename>
				</tradenames>
				<class type="func"> Antidiabetic</class>
				<class type="chem"> Sulfonylurea (2nd generation)</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x4316">
				<para>
					<confusion>
						<tradename id="tnidelem4x43160">glyBURIDE</tradename>
						<drug type="generic" refid="idelem4x43160">Glucotrol/glipiZIDE</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x4323">
				<sec_title>Action:</sec_title>
				<para>Causes functioning β cells in pancreas to release insulin, thereby leading to a drop in blood glucose levels; may improve insulin binding to insulin receptors and increase number of insulin receptors with prolonged administration; may also reduce basal hepatic glucose secretion; not effective if patient lacks functioning β cells</para>
			</section>
			<section type="uses" id="sidelem4x4328">
				<sec_title>Uses:</sec_title>
				<para>Type 2 diabetes mellitus</para>
				<section type="none" id="sidelem4x4333">
					<section type="none" id="sidelem4x4334">
						<sec_title>Unlabeled use:</sec_title>
						<para> Gestational diabetes not controlled by diet</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x4339">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to sulfonylureas, type 1 diabetes, diabetic ketoacidosis, renal failure</para>
				<section type="none" id="sidelem4x4344">
					<section type="none" id="sidelem4x4345">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>) Glynase; (C) DiaBeta, geriatric patients, cardiac/thyroid disease, severe renal/hepatic disease, severe hypoglycemic reactions, sulfonamide/sulfonylurea hypersensitivity, G6PD deficiency</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4350">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4353">
					<sec_title>
						<emphasis style="italic">DiaBeta (nonmicronized)</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x4362">
						<label>•</label>
						<sec_title>Adult<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x4362">
								<item>
									<label>•</label>
									<para> 1.25-5 mg initially, then increase to desired response at weekly intervals up to 20 mg/day; may be given as a single or divided dose</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4369">
						<label>•</label>
						<sec_title>Geriatric<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x4369">
								<item>
									<label>•</label>
									<para> 1.25 mg initially, then increase to desired response; max 20 mg/day, maintenance 1.25-20 mg/day</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x4373">
					<sec_title>
						<emphasis style="italic">Glynase PresTab (micronized)</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x4382">
						<label>•</label>
						<sec_title>Adult<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x4382">
								<item>
									<label>•</label>
									<para> 1.5-3 mg/day initially, may increase by 1.5 mg/wk, max 12 mg/day</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4389">
						<label>•</label>
						<sec_title>Geriatric<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x4389">
								<item>
									<label>•</label>
									<para> 0.75-3 mg/day, may increase by 1.5 mg/wk</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x4393">
					<sec_title>
						<emphasis style="italic">Gestational diabetes (unlabeled)</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x4402">
						<label>•</label>
						<sec_title>Adult (pregnant female)<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x4402">
								<item>
									<label>•</label>
									<para> 2.5 mg/day titrated up to 20 mg/day (conventional glyBURIDE)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4406">
						<sec_title>Available forms:</sec_title>
						<para> Tabs (DiaBeta) 1.25, 2.5, 5 mg (nonmicronized); (Glynase PresTab) 1.5, 3, 6 mg (micronized)</para>
					</section>
					<section type="none" id="sidelem4x4411">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x4415">
								<item>
									<label>•</label>
									<para>With breakfast as single or divided dose; hold dose if patient NPO to avoid hypoglycemia; take at same time each day</para>
								</item>
								<item>
									<label>•</label>
									<para>Gradual conversion from other oral hypoglycemics to product is not needed; insulin ≥20 units/day; convert using 25% reduction in insulin dose every day</para>
								</item>
								<item>
									<label>•</label>
									<para>Micronized glyBURIDE/nonmicronized glyBURIDE are not equivalent</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in tight container in cool environment</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4437">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4440">
					<section type="none" id="sidelem4x4441">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, weakness,</emphasis> paresthesia, tinnitus, fatigue, vertigo</para>
					</section>
					<section type="none" id="sidelem4x4449">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision</para>
					</section>
					<section type="none" id="sidelem4x4454">
						<sec_title>ENDO:</sec_title>
						<para> <emphasis style="bold">Hypoglycemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4461">
						<sec_title>GI:</sec_title>
						<para> Nausea, fullness, heartburn, <emphasis style="bold">hepatotoxicity, cholestatic jaundice,</emphasis> vomiting, diarrhea, <emphasis style="bold">hepatic failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4471">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, thrombocytopenia, agranulocytosis, aplastic anemia (rare),</emphasis> increased AST, ALT, alk phos</para>
					</section>
					<section type="none" id="sidelem4x4479">
						<sec_title>INTEG:</sec_title>
						<para> Rash, allergic reactions, pruritus, urticaria, eczema, photosensitivity, erythema</para>
					</section>
					<section type="none" id="sidelem4x4484">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Angioedema</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4491">
						<sec_title>MS:</sec_title>
						<para> Joint pain, vasculitis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4496">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x4499">
					<section type="none" id="sidelem4x4500">
						<sec_title>PO:</sec_title>
						<para> Completely absorbed by GI route; onset 2 hr; peak 2-4 hr; duration 24 hr; half-life 10 hr; metabolized in liver; excreted in urine, feces (metabolites); crosses placenta; 99% plasma-protein bound</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x4505">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> masking symptoms of hypoglycemia—β-blockers</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> level—digoxin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypoglycemic effects—insulin, MAOIs, oral anticoagulants, chloramphenicol, guanethidine, methyldopa, NSAIDs, salicylates, probenecid, androgens, fenfluramine, fluconazole, gemfibrozil, histamine H<emphasis style="inf">2</emphasis> antagonists, magnesium salts, phenylbutazone, sulfinpyrazone, sulfonamides, tricyclics, urinary acidifiers, β-blockers, clarithromycin, voriconazole</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> LFTs—bosentan; avoid concurrent use</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> triglyceride levels—colesevelam</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of—cycloSPORINE</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> both products’ effects—diazoxide</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> glyBURIDE action—thiazide diuretics, rifampin, isoniazid, cholestyramine, hydantoins, urinary alkalinizers, charcoal, corticosteroids, phenothiazines; oral contraceptives, estrogens, thyroid</para>
				<section type="none" id="sidelem4x4543">
					<section type="none" id="sidelem4x4544">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> antidiabetic effect—garlic, horse chestnut</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> hypoglycemic effect—green tea</para>
					</section>
					<section type="none" id="sidelem4x4555">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT, LDH, BUN, creatinine, alkaline phosphatase</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb, sodium, glucose, platelets, WBC</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4566">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4569">
					<section type="none" id="sidelem4x4570">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x4575">
								<item>
									<label>•</label>
									<para>Hypo/hyperglycemic reaction that can occur soon after meals; for severe hypoglycemia, give IV D<emphasis style="inf">50</emphasis>W, then IV dextrose sol</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4583">
								<item>
									<label>•</label>
									<para>Blood glucose; A1c levels during treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4589">
								<item>
									<para>
										<emphasis alert="nurse">Blood dyscrasias: CBC at baseline, throughout treatment; report decreased blood counts</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4594">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4598">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in polyuria, polydipsia, polyphagia; clear sensorium; absence of dizziness; stable gait; improved serum glucose, A1c</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4604">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4608">
								<item>
									<label>•</label>
									<para>To check for symptoms of cholestatic jaundice: dark urine, pruritus, jaundiced sclera; if these occur, notify prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>To use a blood glucose meter for testing while taking this product</para>
								</item>
								<item>
									<label>•</label>
									<para>About the symptoms of hypo/hyperglycemia, what to do about each</para>
								</item>
								<item>
									<label>•</label>
									<para>That product must be continued on a daily basis; about consequences of discontinuing product abruptly; that in times of stress, infection, surgery, trauma, a higher dose may be needed</para>
								</item>
								<item>
									<label>•</label>
									<para>To take product in morning to prevent hypoglycemic reactions at night if taking once a day</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid OTC medications unless ordered by prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>To report bleeding, bruising, weight gain, edema, shortness of breath, weakness, sore throat</para>
								</item>
								<item>
									<label>•</label>
									<para>That diabetes is a lifelong illness; that product will not cure disease</para>
								</item>
								<item>
									<label>•</label>
									<para>That all food included in diet plan must be eaten to prevent hypoglycemia; to have glucagon emergency kit, sugar packets always available</para>
								</item>
								<item>
									<label>•</label>
									<para>To use sunscreen or stay out of the sun, wear protective clothing (photosensitivity)</para>
								</item>
								<item>
									<label>•</label>
									<para>To carry an emergency ID with prescriber and medication information</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="18" status="active">
			<mono_name>golimumab (Rx)</mono_name>
			<info>
				<pronunciation>(goal-lim′yu-mab)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x46751">Simponi</tradename>
					<tradename id="tnidelem4x46750">Simponi Aria</tradename>
				</tradenames>
				<class type="func"> Antirheumatic agent (disease modifying), immunomodulator</class>
				<class type="chem"> Monoclonal antibody, DMARD, tumor necrosis factor (TNF-α) modifier</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x4685">
				<sec_title>Action:</sec_title>
				<para>Monoclonal antibody specific for human tumor necrosis factor (TNF); elevated levels of TNF are found in patients with rheumatoid arthritis</para>
			</section>
			<section type="uses" id="sidelem4x4690">
				<sec_title>Uses:</sec_title>
				<para>Rheumatoid arthritis (RA), ankylosing spondylitis, psoriatic arthritis, ulcerative colitis</para>
			</section>
			<section type="contra" id="sidelem4x4695">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, active infections</para>
				<section type="none" id="sidelem4x4700">
					<section type="none" id="sidelem4x4701">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, CNS demyelinating disease, Guillain-Barré syndrome, CHF, hepatitis B carriers, blood dyscrasias, surgery, MS, neurologic disease, diabetes, immunosuppression</para>
						<para>
							<bbw>Neoplastic disease, TB; fungal, bacterial, viral infections</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4716">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4719">
					<section type="none" id="sidelem4x4720">
						<sec_title>Rheumatoid arthritis</sec_title>
						<section type="none" id="sidelem4x4728">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x4728">
									<item>
										<label>•</label>
										<para> 50 mg monthly; for RA, give with methotrexate; IV (Simponi Aria only) 2 mg/kg over 30 min, repeat 4 wk later, then q8wk give with methotrexate</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4732">
						<sec_title>Ankylosing spondylitis/psoriatic arthritis</sec_title>
						<section type="none" id="sidelem4x4740">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x4740">
									<item>
										<label>•</label>
										<para> 50 mg monthly</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4744">
						<sec_title>Ulcerative colitis:</sec_title>
						<section type="none" id="sidelem4x4752">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x4752">
									<item>
										<label>•</label>
										<para> 200 mg for 1 dose, then 100 mg in 2 wk, maintenance 100 mg q4wk starting at wk 6</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4756">
						<sec_title>Available form:</sec_title>
						<para> Inj 50 mg/0.5 ml, 100 mg/ml prefilled syringe, SmartJect Auto Injector; inj 50 mg/4 ml single-use vial</para>
					</section>
					<section type="none" id="sidelem4x4761">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x4764">
							<sec_title>SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x4769">
									<item>
										<label>•</label>
										<para>Refrigerate, do not freeze; allow to warm to room temperature before using</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x4774">
									<item>
										<label>•</label>
										<para>Visually inspect sol for particulate or discoloration; sol should be clear to slightly opalescent and colorless to slightly yellow; there may be tiny white particles; do not shake; rotate injection sites</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x4782">
								<label>•</label>
								<sec_title>SmartJect Auto Injector</sec_title>
								<para>
									<list id="lidelem4x4782">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">SmartJect Auto Injector:</emphasis> allow to reach room temperature for 30 min before use; remove cap, and inject within 5 min of removing cap; do not put cap back on; place open end against the inj site at a 90-degree angle without pushing button; push the injector firmly against the skin; press the button once and release; listen for the first click; wait for the second click or 15 sec, then remove injector; do not rub site</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x4789">
								<label>•</label>
								<sec_title>Prefilled syringe</sec_title>
								<para>
									<list id="lidelem4x4789">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Prefilled syringe:</emphasis> allow to warm to room temperature for 30 min; remove needle cover by pulling straight off; do not twist or recap; inject within 5 min of needle cover removal; hold syringe in one hand like a pencil and use other hand to pinch the skin; inject needle at a 45-degree angle; push plunger down as far as it will go; keep pressure on plunger head and remove needle from skin; remove pressure from plunger head; needle guard will cover needle; do not rub site</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
					<section type="none" id="sidelem4x4794">
						<sec_title>IV route</sec_title>
						<para/>
					</section>
					<section type="none" id="sidelem4x4798">
						<sec_title>(Simponi Aria)</sec_title>
						<para>
							<list id="lidelem4x4802">
								<item>
									<label>•</label>
									<para>Calculate number of vials needed; do not shake; dilute total volume of product in NS to yield 100 ml for infusion; slowly add product, mix gently</para>
								</item>
								<item>
									<label>•</label>
									<para>Infuse over 30 min, use infusion set with inline, sterile, nonpyrogenic, low-protein binding filter (≤0.22 mm pore size)</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4813">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4816">
					<section type="none" id="sidelem4x4817">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, paresthesia, <emphasis style="bold">CNS demyelinating disorder,</emphasis> weakness</para>
					</section>
					<section type="none" id="sidelem4x4825">
						<sec_title>CV:</sec_title>
						<para> Hypertension, <emphasis style="bold">CHF</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4832">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="bold">Hepatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4839">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis, aplastic anemia, leukopenia, polycythemia, thrombocytopenia, pancytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4846">
						<sec_title>INTEG:</sec_title>
						<para> Psoriasis</para>
					</section>
					<section type="none" id="sidelem4x4851">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Increased cancer risk,</emphasis> antibody development to this drug; <emphasis style="bold">risk for infection (TB, invasive fungal infections, other opportunistic infections), may be fatal,</emphasis> inj-site reactions</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4862">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Terminal half-life 2 wk</para>
			</section>
			<section type="interactions" id="sidelem4x4867">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x4871">
						<item>
							<label>•</label>
							<para>Do not give concurrently with live vaccines; immunizations should be brought up to date before treatment</para>
						</item>
						<item>
							<label>•</label>
							<para>Dosage change may be needed: warfarin, cycloSPORINE, theophylline</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> infection—abatacept, etanercept, rilonacept, riTUXimab, adalimumab, anakinra, immunosuppressants, inFLIXimab</para>
				<section type="none" id="sidelem4x4886">
					<section type="none" id="sidelem4x4887">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> platelets, WBC</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4898">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4901">
					<section type="none" id="sidelem4x4902">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x4910">
							<label>•</label>
							<sec_title>
								<route>Pain,</route>
							</sec_title>
							<para>
								<list id="lidelem4x4910">
									<item>
										<label>•</label>
										<para> stiffness, ROM, swelling of joints during treatment</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x4914">
								<item>
									<label>•</label>
									<para>Inj-site pain, swelling; usually occur after 2 inj (4-5 days)
<bbw>TB: obtain TB skin test before starting treatment, treat latent TB before starting therapy</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4929">
								<item>
									<para>
										<emphasis alert="nurse">Blood dyscrasias: CBC, differential before and periodically during treatment</emphasis>
<bbw>
											<emphasis alert="lifethreat">Infection:</emphasis> fever, flulike symptoms, dyspnea, change in urination, redness/swelling around any wounds; stop treatment if present; some serious infections including sepsis may occur, may be fatal; patients with active infections should not be started on this product; obtain a chest x-ray, fungal serology, TB testing before starting treatment</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4945">
								<item>
									<label>•</label>
									<para>LFTs; hepatitis B serology, may reactivate HBV</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4953">
							<label>•</label>
							<sec_title>CHF</sec_title>
							<para>
								<list id="lidelem4x4953">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">CHF:</emphasis> B/P, pulse, edema, SOB</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4960">
							<label>•</label>
							<sec_title>Psoriasis</sec_title>
							<para>
								<list id="lidelem4x4960">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Psoriasis:</emphasis> may occur or worsen
<bbw>Neoplastic disease: may occur in those &lt;18 yr, avoid use in those with known malignancies</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4973">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4977">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased inflammation, pain in joints, decreased joint destruction</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4983">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4987">
								<item>
									<label>•</label>
									<para>About self-administration if appropriate: inj should be made in thigh, abdomen, upper arm; rotate sites at least 1 inch from old site; do not inject in areas that are bruised, red, hard</para>
								</item>
								<item>
									<label>•</label>
									<para>That, if medication not taken when due, to inject next dose as soon as remembered and then the following dose as scheduled</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to receive any live virus vaccines during treatment
<bbw>To report signs, symptoms of infection, allergic reaction, or lupuslike syndrome</bbw>
</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is planned or suspected; not to breastfeed</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="19" status="active">
			<mono_name>goserelin (Rx)</mono_name>
			<info>
				<pronunciation>(goe′se-rel-lin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x50230">Zoladex</tradename>
				</tradenames>
				<class type="func"> Gonadotropin-releasing hormone, antineoplastic (hormone)</class>
				<class type="chem"> Synthetic decapeptide analog of LHRH</class>
			</info>
			<section type="actions" id="sidelem4x5033">
				<sec_title>Action:</sec_title>
				<para>Inhibitor of pituitary gonadotropin secretion; initially increases LH and FSH, with increases in testosterone, reduction in sex steroid levels (substitute serum testosterone levels)</para>
			</section>
			<section type="uses" id="sidelem4x5038">
				<sec_title>Uses:</sec_title>
				<para>Advanced and locally confined prostate cancer stage B2-C (10.8 mg), endometriosis, advanced breast cancer, endometrial thinning (3.6 mg)</para>
			</section>
			<section type="contra" id="sidelem4x5043">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity; pregnancy D (breast cancer), X (endometriosis); breastfeeding, children, nondiagnosed vaginal bleeding; hypersensitivity to LHRH, LHRH-agonist analogs; 10.8 mg dose contraindicated in women</para>
				<section type="none" id="sidelem4x5048">
					<section type="none" id="sidelem4x5049">
						<sec_title>Precautions:</sec_title>
						<para> Spinal cord decompression, renal disease, bone mineral density loss, hyperglycemia, diabetes mellitus, CV disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5054">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5057">
					<section type="none" id="sidelem4x5058">
						<sec_title>Breast cancer</sec_title>
						<section type="none" id="sidelem4x5066">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x5066">
									<item>
										<label>•</label>
										<para> 3.6 mg q28days or 10.8 mg q12wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5070">
						<sec_title>Endometrial thinning</sec_title>
						<section type="none" id="sidelem4x5078">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x5078">
									<item>
										<label>•</label>
										<para> 3.6 mg 1-2 depot inj, (usually 1 depot, surgery performed at 4 wk; if 2 depots, surgery performed 2-4 wk after 2nd depot)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5082">
						<sec_title>Available forms:</sec_title>
						<para> Depot inj 3.6, 10.8 mg</para>
					</section>
					<section type="none" id="sidelem4x5087">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x5090">
							<sec_title>Depot</sec_title>
							<para>
								<list id="lidelem4x5094">
									<item>
										<label>•</label>
										<para>SUBCUT using implant, inserted by qualified person into upper subcutaneous tissue in abdominal wall q28days or q12wk (10.8 mg); do not attempt to remove air bubbles from syringe</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5100">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5103">
					<section type="none" id="sidelem4x5104">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headaches,</emphasis><emphasis style="bold">spinal cord compression,</emphasis><emphasis style="italic">anxiety, depression, dizziness, insomnia, lethargy,</emphasis> hot flashes, emotional lability</para>
					</section>
					<section type="none" id="sidelem4x5116">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Dysrhythmia, cerebrovascular accident,</emphasis> hypertension, chest pain, <emphasis style="bold">CHF;</emphasis> MI, sudden cardiac death, stroke (men), <emphasis style="italic">peripheral edema</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5129">
						<sec_title>ENDO:</sec_title>
						<para> Gynecomastia, breast tenderness, breast enlargement, <emphasis style="italic">hot flashes;</emphasis> hyperglycemia, diabetes (men)</para>
					</section>
					<section type="none" id="sidelem4x5137">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> vomiting, constipation, diarrhea, ulcer</para>
					</section>
					<section type="none" id="sidelem4x5145">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Spotting, breakthrough bleeding, decreased libido,</emphasis> renal insufficiency, <emphasis style="bold">urinary obstruction,</emphasis> urinary tract infection, <emphasis style="italic">impotence</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5158">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pain on inj, diaphoresis</para>
					</section>
					<section type="none" id="sidelem4x5163">
						<sec_title>MS:</sec_title>
						<para> Osteoneuralgia</para>
					</section>
					<section type="none" id="sidelem4x5168">
						<sec_title>RESP:</sec_title>
						<para> COPD, URI</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5173">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 12-15 days, half-life 4<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr, 30% protein bound</para>
			</section>
			<section type="interactions" id="sidelem4x5184">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x5187">
					<section type="none" id="sidelem4x5188">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> alk phos, estradiol, FSH, LH, testosterone levels, triglycerides</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> testosterone levels, progesterone</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5199">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5202">
					<section type="none" id="sidelem4x5203">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x5211">
							<label>•</label>
							<sec_title>Reproductive studies</sec_title>
							<para>
								<list id="lidelem4x5211">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Reproductive studies:</emphasis> pelvic ultrasound, pelvic exam, PSA, serum estradiol/testosterone, pregnancy test before therapy</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x5215">
								<item>
									<label>•</label>
									<para>I&amp;O ratios; palpate bladder for distention in urinary obstruction</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5223">
							<label>•</label>
							<sec_title>Cancer metastases</sec_title>
							<para>
								<list id="lidelem4x5223">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Cancer metastases:</emphasis> for relief of bone pain (back pain), change in motor function</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x5227">
								<item>
									<label>•</label>
									<para>Blood studies: lipid profile, acid phosphatase; calcium; hypercalcemia may occur</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5232">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5236">
								<item>
									<label>•</label>
									<para>Therapeutic response: more normal levels of PSA, acid phosphatase, alk phos; testosterone level of &lt;25 ng/dl; thinning of endometrial lining</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5243">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5248">
								<item>
									<label>•</label>
									<para>To continue with appointments monthly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5253">
								<item>
									<label>•</label>
									<para>That hyperglycemia may occur in diabetic patients</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5258">
								<item>
									<label>•</label>
									<para>That gynecomastia and postmenopausal symptoms may occur but will decrease when treatment is discontinued</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5263">
								<item>
									<label>•</label>
									<para>That bone pain may increase then decrease, may use analgesics</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5268">
								<item>
									<label>•</label>
									<para>To notify prescriber of difficulty urinating, hot flashes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5273">
								<item>
									<label>•</label>
									<para>Not to breastfeed; to use effective nonhormonal contraception; to notify prescriber if menstrual period continues</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5281">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if chest pain, weakness, difficulty breathing occur, may indicate MI or stroke</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="20" status="active">
			<mono_name>granisetron (Rx)</mono_name>
			<info>
				<pronunciation>(grane-iss′e-tron)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x52892">Granisol</tradename>
					<tradename id="tnidelem4x52891"/>
					<tradename id="tnidelem4x52890">Sancuso</tradename>
				</tradenames>
				<class type="func"> Antiemetic</class>
				<class type="chem"> 5-HT receptor antagonist</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x5305">
				<sec_title>Action:</sec_title>
				<para>Prevents nausea, vomiting by blocking serotonin peripherally, centrally, and in the small intestine</para>
			</section>
			<section type="uses" id="sidelem4x5310">
				<sec_title>Uses:</sec_title>
				<para>Prevention of nausea, vomiting associated with cancer chemotherapy, including high-dose CISplatin, radiation</para>
				<section type="none" id="sidelem4x5315">
					<section type="none" id="sidelem4x5316">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Acute nausea, vomiting after surgery</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x5321">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, benzyl alcohol</para>
				<section type="none" id="sidelem4x5326">
					<section type="none" id="sidelem4x5327">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, ondansetron/palonosetron/dolasetron hypersensitivity, cardiac dysrhythmias, cardiac/hepatic/GI disease, electrolyte imbalances</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5332">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5335">
					<section type="none" id="sidelem4x5336">
						<sec_title>Nausea, vomiting in chemotherapy</sec_title>
						<section type="none" id="sidelem4x5344">
							<label>•</label>
							<sec_title>Adult and child ≥2 yr<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x5344">
									<item>
										<label>•</label>
										<para> 10 mcg/kg over 5 min, 30 min before the start of cancer chemotherapy;  apply 1 patch (3.1 mg/24 hr) to upper outer arm 24-48 hr before chemotherapy, patch may be worn up to 7 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5354">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5354">
									<item>
										<label>•</label>
										<para> 1 mg bid, give 1st dose 1 hr before chemotherapy and next dose 12 hr after 1st or 2 mg as a single dose anytime within 1 hr before chemotherapy</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5358">
						<sec_title>Nausea, vomiting in radiation therapy</sec_title>
						<section type="none" id="sidelem4x5366">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5366">
									<item>
										<label>•</label>
										<para> 2 mg/day 1 hr before radiation</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5370">
						<sec_title>Available forms:</sec_title>
						<para> Inj 0.1 mg/ml; tab 1 mg; oral sol 2 mg/10 ml; patch TD 3.1 mg/24 hr</para>
					</section>
					<section type="none" id="sidelem4x5375">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x5379">
								<item>
									<label>•</label>
									<para>Chemotherapy/radiation: given on day of chemotherapy or radiation</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5385">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x5389">
									<item>
										<label>•</label>
										<para>Give dose 1 hr before chemotherapy/radiation and another 12 hr after 1st dose</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5395">
							<sec_title>Transdermal</sec_title>
							<para>
								<list id="lidelem4x5399">
									<item>
										<label>•</label>
										<para>Apply to clean, dry skin on upper arm q24-48 hr before chemotherapy</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5405">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x5409">
									<item>
										<label>•</label>
										<para>May give undiluted over 30 sec via <emphasis style="sans-serif">Y</emphasis>-site</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5418">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x5422">
									<item>
										<label>•</label>
										<para>Dilute in 0.9% NaCl for inj or D<emphasis style="inf">5</emphasis>W (20-50 ml); give over 5-15 min 30 min before chemotherapy</para>
									</item>
									<item>
										<label>•</label>
										<para>Store at room temperature for 24 hr after dilution</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Solution compatibilities:</emphasis> D<emphasis style="inf">5</emphasis>W, 0.9% NaCl</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acetaminophen, alemtuzumab, alfentanil, allopurinol, amifostine, amikacin, aminophylline, amphotericin B cholesteryl, ampicillin, ampicillin/sulbactam, amsacrine, aztreonam, bleomycin, bumetanide, buprenorphine, butorphanol, calcium gluconate, CARBOplatin, carmustine, ceFAZolin, cefepime, cefonicid, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chlorproMAZINE, cimetidine, ciprofloxacin, CISplatin, cladribine, clindamycin, cyclophosphamide, cytarabine, dacarbazine, DACTINomycin, DAUNOrubicin, dexamethasone, diphenhydrAMINE, DOBUTamine, DOPamine, DOXOrubicin, DOXOrubicin liposome, doxycycline, droperidol, enalaprilat, etoposide, famotidine, filgrastim, fluconazole, fluorouracil, floxuridine, fludarabine, furosemide, gallium, ganciclovir, gentamicin, haloperidol, heparin hydrocortisone, HYDROmorphone, hydrOXYzine, IDArubicin, ifosfamide, imipenem-cilastatin, leucovorin, LORazepam, magnesium sulfate, melphalan, meperidine, mesna, methotrexate, methylPREDNISolone, metoclopramide, metroNIDAZOLE, mezlocillin, miconazole, minocycline, mitoMYcin, mitoXANtrone, morphine, nalbuphine, netilmicin, ofloxacin, PACLitaxel, piperacillin, piperacillin/tazobactam, plicamycin, potassium chloride, prochlorperazine, promethazine, propofol, ranitidine, sargramostim, sodium bicarbonate, streptozocin, teniposide, thiotepa, ticarcillin, ticarcillin/clavulanate, tobramycin, trimethoprim-sulfamethoxazole, vancomycin, vinBLAStine, vinCRIStine, vinorelbine, voriconazole, zidovudine, zoledronic acid</para>
						</section>
						<section type="none" id="sidelem4x5449">
							<sec_title>Transdermal route</sec_title>
							<para>
								<list id="lidelem4x5453">
									<item>
										<label>•</label>
										<para>Apply to dry, clean, intact skin of upper outer arm 24-48 hr before chemotherapy, firmly press on skin, keep on during chemotherapy; can bathe, avoid swimming, whirlpool; remove ≥24 hr after chemotherapy completion; do not cut patch</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5459">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5462">
					<section type="none" id="sidelem4x5463">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, asthenia,</emphasis> anxiety, dizziness, EPS (rare)</para>
					</section>
					<section type="none" id="sidelem4x5471">
						<sec_title>CV:</sec_title>
						<para> Hypertension, <emphasis style="bold">QT prolongation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5478">
						<sec_title>GI:</sec_title>
						<para> Diarrhea, <emphasis style="italic">constipation,</emphasis> increased AST, ALT, <emphasis style="italic">nausea</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5488">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia,</emphasis> anemia, <emphasis style="bold">thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5498">
						<sec_title>MISC:</sec_title>
						<para> Rash, <emphasis style="bold">bronchospasm</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5505">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized in liver to an active metabolite, half-life 10-12 hr, protein binding 65%</para>
			</section>
			<section type="interactions" id="sidelem4x5510">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> EPS—antipsychotics</para>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation—amoxapine, arsenic, β-blockers, chloroquine, class IA, III antidysrhythmics, cloZAPine, dasatinib, dolasetron, dronedarone, droperidol, erythromycin, flecainide, fluconazole, halogenated/local anesthetics, haloperidol, lapatinib, maprotiline, methadone, octreotide, ondansetron, palonosetron, pentamidine, phenothiazines, pimozide, posaconazole, propafenone, ranolazine, risperiDONE, sertindole, SUNItinib, tacrolimus, telithromycin, tricyclics, troleandomycin, vardenafil, voriconazole, vorinostat, ziprasidone</emphasis>
				</para>
			</section>
			<section type="considerations" id="sidelem4x5520">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5523">
					<section type="none" id="sidelem4x5524">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x5529">
								<item>
									<label>•</label>
									<para>For absence of nausea, vomiting during chemotherapy</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5537">
							<label>•</label>
							<sec_title>Hypersensitivity reaction</sec_title>
							<para>
								<list id="lidelem4x5537">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypersensitivity reaction:</emphasis> rash, bronchospasm</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5544">
							<label>•</label>
							<sec_title>Extrapyramidal symptoms</sec_title>
							<para>
								<list id="lidelem4x5544">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Extrapyramidal symptoms:</emphasis> grimacing, shuffling gait, tremors, involuntary movements, rare</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5551">
							<label>•</label>
							<sec_title>QT prolongation<route> monitor ECG in those with heart disease, renal disease, or the elderly</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x5554">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5558">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of nausea, vomiting during cancer chemotherapy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5564">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5568">
								<item>
									<label>•</label>
									<para>To report diarrhea, constipation, rash, changes in respirations</para>
								</item>
								<item>
									<label>•</label>
									<para>That headache requiring an analgesic is common</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="21" status="active">
			<mono_name>guaiFENesin (<emphasis style="smallcaps">otc</emphasis>, Rx)</mono_name>
			<info>
				<pronunciation>(gwye-fen′e-sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x558823">Alfen</tradename>
					<tradename id="tnidelem4x558822">Altarussin</tradename>
					<tradename id="tnidelem4x558821">
						<country code="CAN">Balminil </country>
					</tradename>
					<tradename id="tnidelem4x558820">
						<country code="CAN">Benylin Chest Congestion Extra Strength </country>
					</tradename>
					<tradename id="tnidelem4x558819">
						<country code="CAN">Benylin E </country>
					</tradename>
					<tradename id="tnidelem4x558818">
						<country code="CAN">Bismutal </country>
					</tradename>
					<tradename id="tnidelem4x558817">Bronchophan</tradename>
					<tradename id="tnidelem4x558816">
						<country code="CAN">Calmylin Expectorant </country>
					</tradename>
					<tradename id="tnidelem4x558815">
						<country code="CAN">Cough Syrup Expectorant </country>
					</tradename>
					<tradename id="tnidelem4x558814">Diabetic Tussin</tradename>
					<tradename id="tnidelem4x558813">
						<country code="CAN">Expectorant </country>
					</tradename>
					<tradename id="tnidelem4x558812">
						<country code="CAN">Expectorant Syrup </country>
					</tradename>
					<tradename id="tnidelem4x558811">Guiatuss</tradename>
					<tradename id="tnidelem4x558810">
						<country code="CAN">Jack &amp; Jill </country>
					</tradename>
					<tradename id="tnidelem4x55889">Miltuss EX</tradename>
					<tradename id="tnidelem4x55888">Mucinex</tradename>
					<tradename id="tnidelem4x55887">Naldecon Senior EX</tradename>
					<tradename id="tnidelem4x55886">Organidin NR</tradename>
					<tradename id="tnidelem4x55885">Robitussin Guaifenesin</tradename>
					<tradename id="tnidelem4x55884">Scot-Tussin Expectorant</tradename>
					<tradename id="tnidelem4x55883">Siltussin DAS</tradename>
					<tradename id="tnidelem4x55882">Siltussin SA</tradename>
					<tradename id="tnidelem4x55881">
						<country code="CAN">Vicks Chest Congestion Relief </country>
					</tradename>
					<tradename id="tnidelem4x55880">
						<country code="CAN">Vicks DayQuil Mucus Control </country>
					</tradename>
				</tradenames>
				<class type="func"> Expectorant</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x5626">
				<sec_title>Action:</sec_title>
				<para>Increases the volume and reduces the viscosity of secretions in the trachea and bronchi to facilitate secretion removal</para>
			</section>
			<section type="uses" id="sidelem4x5631">
				<sec_title>Uses:</sec_title>
				<para>Productive and nonproductive cough</para>
			</section>
			<section type="contra" id="sidelem4x5636">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity; chronic, persistent cough</para>
				<section type="none" id="sidelem4x5641">
					<section type="none" id="sidelem4x5642">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, CHF, asthma, emphysema, fever</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5647">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5655">
					<label>•</label>
					<sec_title>Adult and adolescent<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x5655">
							<item>
								<label>•</label>
								<para> 200-400 mg q4hr;  600-1200 mg q12hr, max 2.4 g/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5665">
					<label>•</label>
					<sec_title>Child 6-11 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x5665">
							<item>
								<label>•</label>
								<para> 100-200 mg q4hr;  600 mg q12hr, max 1.2 g/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5675">
					<label>•</label>
					<sec_title>Child 2-5 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x5675">
							<item>
								<label>•</label>
								<para> 50-100 mg q4hr; max 600 mg/day; ext rel 300 mg q12hr, max 600 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5679">
					<section type="none" id="sidelem4x5680">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 100, 200, 400 mg; oral sol 100 mg/5 ml; ext rel tabs 600, 1200 mg; syrup 100 mg/5 ml; oral granules 50, 100 mg/packet, Caps 200 mg; liquid 100, 200 mg/5 ml</para>
					</section>
					<section type="none" id="sidelem4x5685">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x5689">
								<item>
									<label>•</label>
									<para>Do not break, crush, chew ext rel tabs</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5700">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5703">
					<section type="none" id="sidelem4x5704">
						<sec_title>CNS:</sec_title>
						<para> Drowsiness, headache, dizziness</para>
					</section>
					<section type="none" id="sidelem4x5709">
						<sec_title>GI:</sec_title>
						<para> Nausea, anorexia, vomiting, diarrhea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5714">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 1 hr, excreted in urine (metabolites)</para>
			</section>
			<section type="considerations" id="sidelem4x5719">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5722">
					<section type="none" id="sidelem4x5723">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x5731">
							<label>•</label>
							<sec_title>Cough</sec_title>
							<para>
								<list id="lidelem4x5731">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Cough:</emphasis> type, frequency, character, including sputum; fluids should be increased to 2 L/day</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x5735">
								<item>
									<label>•</label>
									<para>Increased fluids, room humidification to liquefy secretions</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5740">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5744">
								<item>
									<label>•</label>
									<para>Therapeutic response: productive cough, thinner secretions</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5750">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5754">
								<item>
									<label>•</label>
									<para>To avoid driving, other hazardous activities if drowsiness occurs (rare)</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid smoking, smoke-filled room, perfumes, dust, environmental pollutants, cleansers</para>
								</item>
								<item>
									<label>•</label>
									<para>To consult health provider if cough lasts &gt;7 days</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
</alpha>
</drug_guide>